



Publications with genetically modified mouse models in Pharma

* indicates collaborative study with partners from industry

Table of Contents

Reviews on mouse models for atherosclerosis and metabolic disease	2
APOE*3Leiden.huCETP and APOE*3Leiden transgenic mice as translational models for modulation of lipoprotein metabolism and atherosclerosis.....	3
Lipid studies in APOE*3Leiden.huCETP transgenic mice	3
Atherosclerosis studies in APOE*3Leiden.huCETP transgenic mice.....	4
Lipid studies in APOE*3Leiden transgenic mice	6
Atherosclerosis studies in APOE*3Leiden transgenic mice	9
Vascular and cognitive function, stroke, myocardial infarction.....	13
MASLD, MASH and liver fibrosis	14
Muscle health and frailty	19
Obesity, insulin resistance, type 2 diabetes and fatty acid metabolism.....	19
Chronic inflammation and inflammatory diseases	25
Drug and dietary intervention studies in huCRP transgenic mice	26
Drug and dietary intervention studies in other genetically modified mouse models	27
Other references related to transgenic mouse models	28



Reviews on mouse models for atherosclerosis and metabolic disease

Zadelaar ASM, Kleemann R, Verschuren L, de Vries-van der Weij J, van der Hoorn J, Princen HM, Kooistra T. Mouse models for atherosclerosis and pharmaceutical modifiers. **Arterioscler Thromb Vasc Biol** 2007; 27: 1706-1721. doi:10.1212/WNL.000000000000201538.

Kühnast S, Fiocco M, van der Hoorn JWA, Princen HMG, Jukema JW. Innovative pharmaceutical interventions in cardiovascular disease: focusing on the contribution of non-HDL-C/ LDL-C-lowering versus HDL-C-raising - A systematic review and meta-analysis of relevant preclinical studies and clinical trials. **Eur J Pharmacol** 2015; 763: 48-63. doi: 10.1016/j.ejphar.2015.03.089

van den Brink W, van Bilsen J, Salic K, Hoevenaars FPM, Verschuren L, Kleemann R, Bouwman J, Ronnett GV, van Ommen B, Wopereis S. Current and future nutritional strategies to modulate inflammatory dynamics in metabolic disorders. **Front Nutr** 2019; 6: 129. doi: 10.3389/fnut.2019.00129.

Princen HMG, Pouwer MG, Pieterman EJ. Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. **Toxicol. Rep.** 2016 (3) 46–54. **Toxicol Rep** 2016; 3: 306-309.

Morrison MC, Kleemann R. Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies. **Front Immunol** 2015; 6: 308. doi: 10.3389/fimmu.2015.00308.

Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM, Kleemann R, van den Hoek AM. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. **PLoS ONE** 2014; 9: e115922. doi: 10.1371/journal.pone.0115922.

Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. **Cardiovasc Res** 2008; 79: 360-376.

Van Diepen JA, Berbée JFP, Havekes LM, Rensen PCN. Interactions between inflammation and lipid metabolism: Relevance for efficacy of anti-inflammatory drugs in treatment of atherosclerosis. **Atherosclerosis** 2013; 228: 306-315.

Auvinen HE, Romijn JA, Biermasz NR, Havekes LM, Smit JW, Rensen PC, Pereira AM. Effects of high fat diet on the Basal activity of the hypothalamus-pituitary-adrenal axis in mice: a systematic review. **Horm Metab Res** 2011; 43 : 899-906.

Voshol PJ, Rensen PC, van Dijk KW, Romijn JA, Havekes LM. Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. **Biochim Biophys Acta** 2009 1791: 479-485.

Wheelock E, Wheelock AM, Kawashima S, Diez D, Kanehisa M, van Erk M, Kleemann R, Haeggström JZ, Goto S. Systems biology approaches and pathway tools for investigating cardiovascular disease. **Mol Bio Syst** 2009; 5:1-15.

Romijn JA, Corssmit EP, Havekes LM, Pijl H. Gut-brain axis. **Curr Opin Clin Nutr Metab Care** 2008; 11: 518-521.

De Ruiter MC, Alkemade FE, Gittenberger-de Groot AC, Poelmann RE, Havekes LM, van Dijk KW. Maternal transmission of risk for atherosclerosis. **Curr Opin Lipidol** 2008; 19: 333-337.

Heijboer AC, Pijl H, Van den Hoek AM, Havekes LM, Romijn JA, Corssmit EP. Gut-brain axis: regulation of glucose metabolism. **J Neuroendocrinol** 2006; 18: 883-894.

den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. **Arterioscler Thromb Vasc Biol** 2004; 24: 644-649.

Fliers E, Kreier F, Voshol PJ, Havekes LM, Sauerwein HP, Kalsbeek A, Buijs RM, Romijn JA. White adipose tissue: getting nervous. **J Neuroendocrinol** 2003; 15: 1005-10.

Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. **J Hepatol** 2001; 35: 816-822.

Hofker MH, van Vlijmen BJM, Havekes LM. Transgenic mouse models to study the role of APOE in hyperlipidemia and

atherosclerosis. **Atherosclerosis** **1998**; 137: 1-11.

Krause BR, Princen HMG. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? **Atherosclerosis** **1998**; 140: 15-24. *

APOE*3Leiden.huCETP and APOE*3Leiden transgenic mice as translational models for modulation of lipoprotein metabolism and atherosclerosis

Lipid studies in APOE*3Leiden.huCETP transgenic mice

Suchowerska AK, Stokman G, Palmer JT, Coghlan PA, Pieterman EJ, Keijzer N, Lambert G, Chemello K, Jaafar AK, Parmar J, Yan L, Tong Y, Mu L, Princen HMG, Bonnar J, Evison BJ. A novel, orally bioavailable, small-molecule inhibitor of PCSK9 with significant cholesterol-lowering properties in vivo. **J Lipid Res** **2022**; 63(11) 100293. doi.org/10.1016/j.jlr.2022.100293. *

Pieterman E, Princen HMG, Jarke A, Nilsson R, Cavallin A, Bergenholm L, Henricsson M, Gopaul VS, Agrawal R, Nissen S, Hurt-Camejo E. Chronic oral administration of mineral oil compared with corn oil: Effects on gut permeability and plasma inflammatory and lipid biomarkers. **Front Pharmacol** **2021**; 12: 681455. doi: 10.3389/fphar.2021.681455. *

Pouwer MG, Pieterman EJ, Chang S-C, Olsen GW, Caspers MPM, Verschuren L, Jukema JW, Princen HMG. Dose effects of ammonium perfluorooctanoate on lipoprotein metabolism in APOE*3-Leiden.CETP mice. **Toxicol Sciences** **2019**; 168: 519-534. <https://doi.org/10.1093/toxsci/kfz015>. *

Hoeke G, Wang Y, van Dam AD, Mol IM, Gart E, Klop HG, van den Berg SM, Pieterman EH, Princen HMG, Groen AK, Rensen PCN, Berbée JFP, Boon MR. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. **Atherosclerosis** **2017**; 267: 116-126. doi: 10.1016/j.atherosclerosis.2017.10.030.

Van der Tuin SJL, Kühnast S, Berbée JFP, Verschuren L, Pieterman E, Havekes LM, van der Hoorn JWA, Rensen PCN, Jukema JW, Princen HMG, Willems van Dijk K, Wang Y. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. **J Lipid Res** **2015**; 56: 2085-2093. doi: 10.1194/jlr.M057794.

Van den Hoek AM, van der Hoorn JWA, Maas AC, van den Hoogen RM, van Nieuwkoop A, Droog S, Offerman EH, Pieterman EJ, Havekes LM, Princen HMG. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the Metabolic Syndrome. **Diabet Obes Metab** **2014**; 16: 537-544.

Gautier T, de Haan W, Grober J, Ye D, Bahr MJ, Claudel T, Nijstad N, Van Berkel TJ, Havekes LM, Manns MP, Willems SM, Hogendoorn PC, Lagrost L, Kuipers F, Van Eck M, Rensen PC, Tietge UJ. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. **J Lipid Res** **2013**; 54: 2195-2205. doi: 10.1194/jlr.M038141.

Wei H, Hu C, Wang M, van den Hoek AM, Reijmers TH, Wopereis S, Bouwman J, Ramaker R, Korthout HAAJ, Vennik M, Hankemeier T, Havekes LM, Witkamp RF, Verheij ER, Xu G, van der Greef J. Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice. **PLOS One** **2012**; 7: e30332. *

Li Z, Hildebrand RB, Wang Y, van der Hoorn JWA, Princen HMG, van Eck M, Rensen PCN, van Berkel TJC, Hoekstra M. Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. **Biochem Pharmacol** **2012**; 84: 821-829.

Bijland S, Rensen PCN, Pieterman EJ, Maas ACE, van der Hoorn JWA, van Erk MJ, Havekes LM, Willems van Dijk K, Chang SC, Ehresman DJ, Bütenhoff JL, Princen HMG. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden.CETP mice. **Toxicol Sciences** **2011**; 123: 290-303. *

Wang Y, Berbee JF, Stroes ES, Smit JW, Havekes LM, Romijn JA, Rensen PC. CETP expression reverses the reconstituted HDL-induced increase in VLDL. **J Lipid Res** **2011**; 52:1533-1541.

Hu C, Wei H, van den Hoek AM, Wang M, van der Heijden R, Spijksma G, Reijmers TH, Bouwman J, Wopereis S, Havekes LM, Verheij E, Hankemeier T, Xu G, van der Greef J. Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice. **PLoS One** **2011**; 6: e19423. Epub 2011 May 17. *

Bijland S, Pieterman EJ, Maas ACE, van der Hoorn JWA, van Erk MJ, van Klinken JB, Havekes LM, Willems van Dijk K, Princen HMG, Rensen PCN. Fenofibrate increases very low density lipoprotein-triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice. **J Biol Chem** 2010; 285: 25168-25175. *

Bijland S, van den Berg SAA, Voshol PJ, van den Hoek AM, Princen HMG, Havekes LM, Rensen PCN, Willems van Dijk K. CETP does not affect triglyceride production or clearance in APOE*3-leiden mice. **J Lipid Res** 2010; 51: 97-102.

De Vries-van der Weij J, de Haan W, Hu I, Kuif M, Oei HLDW, van der Hoorn JWA, Havekes LM, Princen HMG, Romijn JA, Smit JWA, Rensen PCN. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. **Endocrinology** 2009; 150: 2368-2375.

De Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn JA, Jukema JW, Havekes LM, Princen HMG, Rensen PCN. PXR agonism decreases HDL levels in APOE*3-Leiden.CETP mice. **Biochim Biophys Acta** 2009; 1791: 191-197.

Van der Hoorn JWA, de Haan W, Berbée JFP, Havekes LM, Jukema JW, Rensen PCN, Princen HMG. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3-Leiden.CETP mice. **Arterioscler Thromb Vasc Biol** 2008; 28: 2016-2022.

De Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HMG, Romijn JA, Jukema JW, Havekes LM, Rensen PCN. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. **Atherosclerosis** 2008; 197: 57-63.

Van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HMG, Jukema JW, Havekes LM, Rensen PCN. Fenofibrate increases HDL cholesterol by reducing cholesteryl ester transfer protein expression. **J Lipid Res** 2007; 48: 1763-1771.

Atherosclerosis studies in APOE*3Leiden.huCETP transgenic mice

Inia JA, Zhang L, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, de Kleer M, Jukema JW, Kastelein JJP, Szarek M, van den Hoek AM, Stokman G, Pieterman EJ, Princen HMG. Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL-clearance and regress atherosclerosis on atorvastatin background. **J Lipid Res** 2026, conditionally accepted. *

Inia JA, van Nieuwkoop-van Straalen A, Jukema JW, Rolin B, Staarup EM, Mogensen CK, Princen HMG, van den Hoek AM. Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis. **J Lipid Res** 2025; 66: 100753. doi.org/10.1016/j.jlr.2025.100753. *

Zancanella V, Vallès A, Liefhebber JMP, Paerels L, Vendrell Tornero C, Wattimury H, van der Zon T, van Rooijen K, Golinska M, Grevelink T, Ehlert E, Pieterman EJ, Keijzer N, Princen HMG, Stokman G, Poi Liu Y. Proof-of-concept study for liver-directed miQURE® technology in a dyslipidemic mouse model. **Mol Therap Nucleic Acids** 2023; 32 : 454-467. doi.org/10.1016/j.omtn.2023.04.004. *

Carracedo M, Pawelzik SC, Artiach G, Pouwer MG, Plunde O, Saliba-Gustafsson P, Ehrenborg E, Eriksson P, Pieterman E, Stenke L, Princen HMG, Franco-Cereceda A, Bäck M. The tyrosine kinase inhibitor nilotinib targets the discoidin domain receptor DDR2 in calcific aortic valve stenosis. **Br J Pharmacol** 2022; 1-13. doi: 10.1111/bph.15911.

Härdtner C, Kornemann J, Krebs K, Ehlert CA, Jander A, Zou J, Starz C, Rauterberg S, Sharipova D, Dufner B, Hoppe N, Dederichs TS, Willecke F, Stachon P, Heidt T, Wolf D, von zur Mühlen C, Madl J, Kohl P, Käser R, Böttler T, Pieterman EJ, Princen HMG, Ho-Tin-Noé B, Swirski FK, Robbins CS, Bode C, Zirik A, Hilgendorf I. Inhibition of macrophage proliferation dominates plaque regression in response to cholesterol lowering. **Basic Res Cardiol** 2020, 115: 78 (1-19). doi.org/10.1007/s00395-020-00838-4.

Stokman G, van den Hoek AM, Denker Thorbeek D, Pieterman EJ, Veidal SS, Basta B, Iruarizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjaeret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. **Liver Int** 2020; 40: 2860-2876. doi: 10.1111/liv.14643. *

Pouwer MG, Pieterman EJ, Worms N, Keijzer N, Jukema JW, Gromada J, Gusarova V, Princen HMG. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. **J Lipid**

Res 2020; 61: 365-375. doi:10.1194/jlr.RA119000419. *

van Keulen D, Pouwer MG, Emilsson V, Perisic Matic L, Pieterman EJ, Hedin U, Gudnason V, Jennings LL, Holmström K, Schnack Nielsen B, Pasterkamp G, Lindeman JHN, van Gool AJ, Sollewijn Gelpke MD, Princen HMG, Tempel D. Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans. **PLoS One** **2019**;14(8): e0221477. doi.org/10.1371/journal.pone.0221477.

Schuster S, Rubil S, Endres M, Princen HMG, Boeckel JN, Winter K, Werner C, Laufs U. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice. **Sci Rep** **2019**; 9: 11079. doi.org/10.1038/s41598-019-47242-0.

van Keulen D, Pouwer MG, Pasterkamp G, van Gool AJ, Sollewijn Gelpke MD, Princen HMG, Tempel D. Inflammatory cytokine oncostatin M induces endothelial activation in macro- and microvascular endothelial cells and in APOE*3Leiden.CETP mice. **PLoS One** **2018**;13(10): e0204911. doi: 10.1371/journal.pone.0204911.

Pouwer MG, Pieterman EJ, Verschuren L, Caspers MPM, Kluft C, Garcia RA, Aman J, Jukema JW, Princen HMG. The BCR-ABL1 inhibitors imatinib and ponatinib decrease plasma cholesterol and atherosclerosis, and nilotinib and ponatinib activate coagulation in a translational mouse model. **Front Cardiovasc Med** **2018**; 5: 55. doi: 10.3389/fcvm.2018.00055. *

Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stah NI, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YDI, on behalf of the TAICHI consortium, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Berg Wulff A, Nordestgaard BG, Tybjaerg-Hansen A, **van den Hoek AM, Princen HMG**, Ledbetter DH, Carey DJ, on behalf of the Geisinger-Regeneron DiscovEHR Collaboration, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A. Genetic and pharmacologic inactivation of ANGPTL3 and atherosclerotic cardiovascular disease. **New Engl J Med** **2017**; 377: 211-221. doi:10.1056/NEJMoa1612790. *

Landlinger C, Pouwer M, Juno C, van der Hoorn JWA, Pieterman E, Jukema JW, Staffler G, Princen HMG, Galabova G. The AT04A vaccine against PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. **Eur Heart J** **2017**; 38: 2499-2507. doi:10.1093/eurheartj/ehx260 *

Hoeke G, Wang Y, van Dam AD, Mol IM, Gart E, Klop HG, van den Berg SM, Pieterman EJ, Princen HMG, Groen AK, Rensen PCN, Berbée JFP, Boon MR. Atorvastatin accelerates clearance of lipoprotein remnants generated by activated brown fat to further reduce hypercholesterolemia and atherosclerosis. **Atherosclerosis** **2017**; 267: 116-126. doi.org/10.1016/j.atherosclerosis.2017.10.030.

Simic B, Mocharla P, Crucet M, Osto E, Kratzer A, Stivala S, Kühnast S, Speer T, Doycheva P, Princen HM, van der Hoorn JW, Jukema JW, Giral H, Tailleux A, Landmesser U, Staels B, Lüscher TF. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. **Atherosclerosis** **2017**; 257:186-194. doi: 10.1016/j.atherosclerosis.2017.01.011.

Kühnast S, van der Tuin SJL, van der Hoorn JWA, van Klinken JB, Simic B, Pieterman E, Havekes LM, Landmesser U, Lüscher TF, Willems van Dijk K, Rensen PCN, Jukema JW, Princen HMG. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDLcholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. **Eur Heart J** **2015**; 36: 39-48. doi:10.1093/eurheartj/ehu319.

Ason B, van der Hoorn JWA, Chan J, Lee E, Pieterman EJ, Khanh Nguyen K, Di M, Shetterly S, Tang J, Yeh WC, Schwarz M, Jukema JW, Scott R, Wasserman SM, Princen HMG, Jackson S. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol and atherosclerosis in the absence of ApoE. **J Lipid Res** **2014**; 55: 2370-2379. doi:10.1194/jlr.M053207. *

Kühnast S, van der Hoorn JWA, Pieterman EJ, van den Hoek AM, Sasiela WJ, Gusarova V, Peyman A, Schäfer HL, Schwahn U, Jukema JW, Princen HMG. Alirocumab inhibits atherosclerosis, improves plaque morphology, and enhances the effects of a statin. **J Lipid Res** **2014**; 55: 2103-2112. doi:10.1194/jlr.M051326 *

Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJL, Zhang H, Bieghs V, Jawad AHM, Shiri-Sverdlov R, Bot I, de Jager SCA, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PCN. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. **Br J Pharmacol** **2014**; 171: 723-734.

Kühnast S, Louwe MC, Heemskerk MM, Pieterman EJ, van Klinken JB, van den Berg SAA, Smit JWA, Havekes LM, Rensen PCN, van der Hoorn JWA, Princen HMG, Jukema JW. Niacin reduces atherosclerosis development in APOE*3Leiden.CETP mice mainly by reducing nonHDL-cholesterol. **PLOS One** **2013**; 8: e66467: 1-13.

Gierman LM, Kühnast S, Koudijs A, Pieterman EJ, Kloppenburg M, van Osch GJ, Stojanovic-Susulic V, Huizinga TW, Princen HM, Zuurmond AM. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis. **Ann Rheum Dis** **2014**; 73: 921-927. doi: 10.1136/annrheumdis 2013-203248.

Auvinen HE, Wang Y, Princen H, Romijn JA, Havekes LM, Smit JWA, Meijer OC, Biermasz NR, Rensen PCN, Pereira AM. Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-Leiden.CETP mice. **PLOS One** **2013**; 8: e63882: 1-10.

Berbée JFP, Wong MC, Wang Y, van der Hoorn JWA, Khedoe PPSJ, van Klinken JB, Mol IM, Hiemstra PS, Tsikas D, Romijn JA, Havekes LM, Princen HMG, Rensen PCN. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. **J Nutr Biochem** **2013**; 24: 1423-1430.

Kühnast S, van der Hoorn JWA, van den Hoek AM, Havekes LM, Liau GW, Jukema JW, Princen HMG. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. **J Hypertension** **2012**; 30: 107-116. *

Van der Hoorn, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PCN, Princen HMG. The dual PPAR α /y agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3-Leiden.CETP transgenic mice. **Brit J Pharmacol** **2009**; 156: 1067-1075. *

De Vries-van der Weij J, Zadelaar S, Toet K, Havekes LM, Kooistra T, Rensen PC. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol. **Atherosclerosis** **2009**; 206: 153-158.

De Haan W, de Vries-van der Weij J, van der Hoorn JWA, Gautier T, van der Hoogt CC, Westerterp M, Romijn JA, Jukema JW, Havekes LM, Princen HMG, Rensen PCN. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more pro-inflammatory lesions than atorvastatin. **Circulation** **2008**; 117: 2515-2522.

Westerterp M, Van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PCN. Cholesteryl ester transfer protein decreases HDL and severely aggravates atherosclerosis in APOE*3Leiden mice. **Arterioscler Thromb Vasc Biol** **2006**; 26: 2552-2559.

Lipid studies in APOE*3Leiden transgenic mice

Sugimoto-Kawabata K, Shimada H, Sakai K, Suzuki K, Kelder T, Pieterman EJ, Cohen LH, Havekes LM, Princen HM, van den Hoek AM. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. **J Lipid Res** **2013**; 54: 1255-1264. *

van de Steeg E, Kleemann R, Jansen HT, van Duyvenvoorde W, Offerman EH, Wortelboer HM, deGroot J. Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials. **J Pharmacol Exp Ther** **2013**; 347: 635-644.

Verschuren L, Radonjic M, Wielinga PY, Kelder T, Kooistra T, van Ommen B, Kleemann R. Systems biology analysis unravels the complementary action of combined rosuvastatin and ezetimibe therapy. **Pharmacogenet Genomics** **2012**; 12:837-45. doi: 10.1097/FPC.0b013e328359d274.

Kirwan GM, Johansson E, Kleemann R, Verheij ER, Wheelock AM, Goto S, Trygg J, Wheelock CE. Building multivariate systems biology models. **Anal Chem** **2012**; 84: 7064-7071.

Wielinga PY, Verschuren L, Harthoorn LF, Schoemaker M, Jouni ZE, van Tol EAF, Kleemann R, Kooistra T. Supplementation of an arachidonic acid – docosahexaenoic acid mixture during early life reduces body weight gain, plasma lipids and adiposity later in life in ApoE3Leiden mice. **Mol Nutr Food Res** **2012**; 56: 1081-1089. *

Parlevliet ET, Wang Y, Geerling JJ, Schröder-Van der Elst JP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H, Rensen PC. GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. **PLOS One** **2012**; 7(11):e49152. doi:

10.1371/journal.pone.0049152. *

Van Diepen JA, Wong MC, Guigas B, Bos J, Stienstra R, Hodson L, Shoelson SE, Berbée JF, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Hepatocyte-specific IKK- β activation enhances VLDL-triglyceride production in APOE*3-Leiden mice. **J Lipid Res** 2011; 52: 942-950. Epub 2011 Feb 28

Thissen U, Wopereis S, van den Berg SAA, Bobeldijk I, Kleemann R, Kooistra T, Willems van Dijk K, van Ommen B, Smilde AK. Improving the analysis of designed studies by combining statistical modelling with study design information. **BMC Bioinformatics** 2009; Feb 7; 10: 52.

Plat J, de Jong A, Volger OL, Princen HMG, Mensink RP. Preferential campesterol incorporation into various tissues in APOE*3-Leiden mice consuming plant sterols and stanols. **Metabolism** 2008; 57: 1241-1247. *

Ricketts ML, Boekschoten MV, Kreeft AJ, Hooiveld GJEJ, Moen CJA, Müller M, Frants RR, Kasanmoentalib S, Post SM, Princen HMG, Porter JG, Katan MB, Hofker MH, Moore DD. The cholesterol-raising factor from coffee beans, cafestol, as an agonist ligand for the farnesoid and pregnane X receptors. **Mol Endocrinol** 2007; 21: 1603-1616.

Post SM, Groenendijk M, van der Hoogt CC, Fievet C, Luc G, Hoekstra M, Princen HMG, Staels B, Rensen PCN. Cholesterol 7 α -hydroxylase deficiency in mice on an APOE*3-Leiden background increases hepatic ABCA1 mRNA expression and HDL-cholesterol. **Arterioscler Thromb Vasc Biol** 2006; 26: 2724-2730.

Duivenvoorden I, Voshol PJ, Rensen PCN, van Duyvenvoorde W, Romijn JA, Emeis JJ, Havekes LM, Nieuwenhuizen WF. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3-Leiden mice. **Amer J Clin Nutr** 2006; 84: 312-321

Den Boer MA, Berbee JF, Reiss P, van der Valk M, Voshol PJ, Kuipers F, Havekes LM, Rensen PC, Romijn JA. Ritonavir impairs lipoprotein lipase-mediated lipolysis and decreases uptake of fatty acids in adipose tissue. **Arterioscler Thromb Vasc Biol** 2006; 26: 124-129.

Kreeft A, Moen CJ, Porter G, Kasanmoentalib S, Sverdllov R, van Gorp PJ, Havekes LM, Frants RR, Hofker MH. Genomic analysis of the response of mouse models to high-fat feeding shows a major role of nuclear receptors in the simultaneous regulation of lipid and inflammatory genes. **Atherosclerosis** 2005;182: 249-57.

De Roos B, Duivenvoorden I, Rucklidge G, Reid M, Ross K, Lamers MJ, Voshol PJ, Havekes LM, Teusink B. Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data. **FASEB J** 2005;19: 813-815.

Duivenvoorden I, Teusink B, Rensen PC, Kuipers F, Romijn JA, Havekes LM, Voshol PJ. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. **J Lipid Res** 2005; 46:988-993.

Delsing DJM, Post SM, Groenendijk M, Solaas K, vanderBoom H, vanDuyvenvoorde W, deWit ECM, Bloks VW, Kuipers F, Havekes LM, Princen HMG. Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-Leiden mice. **J Cardiovasc Pharmacol** 2005; 45: 53-60. *

Espirito Santo SMS, van Vlijmen BJM, Buytenhek R, van Duyvenvoorde W, Havekes LM, Arnault I, Auger J, Princen HMG. Well-characterized garlic-derived materials are not hypolipidemic in ApoE*3-Leiden transgenic mice. **J Nutr** 2004; 134; 1500-1503.

Clish CB, Davidov E, Oresic M, Plasterer TN, Lavine G, Londo T, Meys M, Snell P, Stochaj W, Adourian A, Zhang X, Morel N, Neumann E, Verheij E, Vogels JTWE, Havekes LM, Afeyan N, Regnier F, van der Greef J, Naylor S. Integrative biological analysis of APOE*3-Leiden transgenic mouse. **OMICS J Integr Biol** 2004; 8; 3-13. *

Davidov E, Clish CB, Oresic M, Meys M, Stochaj W, Snell P, Lavine G, Londo TR, Adourian A, Zhang X, Johnston M, Morel N, Marple EW, Plasterer TN, Neumann E, Verheij E, Vogels JT, Havekes LM, van der Greef J, Naylor S. Methods for the differential integrative omic analysis of plasma from a transgenic disease animal model. **OMICS** 2004; 8: 267-288. *

Oresic M, Clish CB, Davidov EJ, Verheij E, Vogels J, Havekes LM, Neumann E, Adourian A, Naylor S, van der Greef J, Plasterer T. Phenotype characterisation using integrated gene transcript, protein and metabolite profiling. **Appl Bioinformatics** 2004; 3: 205-217. *

Post SM, Groenendijk M, Solaas K, Rensen PCN, Princen HMG. Cholesterol 7 α -hydroxylase deficiency in mice on an



ApoE*3-Leiden background impairs very low density lipoprotein production. **Arterioscler Thromb Vasc Biol** 2004; 24: 768-774.

Grefhorst A, Elzinga BM, Voshol PJ, Plösch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. **J Biol Chem** 2002; 277: 34182-3490.

Kreeft AJ, Moen CJA, Hofker MH, Frants RR, Vreugdenhil E, Gijbels MJJ, Havekes LM, Datson NA. Identification of differentially regulated genes in mildly hyperlipidemic ApoE3-Leiden mice by use of serial analysis of gene expression. **Arterioscler Thromb Vasc Biol** 2001; 21: 1984-1990.

Mensenkamp AR, Teusink B, Baller JF, Wolters H, Havinga R, van Dijk KW, Havekes LM, Kuipers F. Mice expressing only the mutant apoE*3Leiden gene show impaired VLDL secretion. **Arterioscler Thromb Vasc Biol** 2001; 21: 1366-1372.

Volger OL, van der Boom H, de Wit ECM, van Duyvenvoorde W, Hornstra G, Plat J, Havekes LM, Mensink RP, Princen HMG. Dietary plant stanol esters reduce VLDL-cholesterol secretion and bile saturation in apoE*3Leiden transgenic mice. **Arterioscler Thromb Vasc Biol** 2001; 21: 1046-1052. *

Mensenkamp AR, van Luyn MJA, van Goor H, Bloks V, Apostel F, Greeve J, Hofker MH, Jong MC, van Vlijmen BJM, Havekes LM, Kuipers F. Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. **J Hepatology** 2000; 33: 189-198.

Post SM, de Roos B, Vermeulen M, Afman L, Jong MC, Dahlmans VEH, Havekes LM, Stellaard F, Katan MB, Princen HMG. Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis. **Arterioscler Thromb Vasc Biol** 2000; 20: 1551-1556.

van Dijk KW, van Vlijmen BJ, de Winther MP, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH. Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression. **Arterioscler Thromb Vasc Biol** 1999; 19: 2945-2951.

Van Vlijmen BJM, Mensink RP, van 't Hof HB, Offermans RFG, Hofker MH, Havekes LM. Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice. **J Lipid Res** 1998; 39: 1181-1188.

Van Vlijmen BJM, Pearce NJ, Bergö M, Staels B, Yates JW, Gribble AD, Bond BC, Hofker MH, Havekes LM, Groot PHE. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. **Drug Res** 1998; 48: 396-402. *

Willems van Dijk K, van Vlijmen BJM, van der Zee A, van 't Hof B, van der Boom H, Kobayashi K, Chan L, Havekes LM, Hofker MH. Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. **Arterioscler Thromb Vasc Biol** 1998; 18: 7-12.

Van Vlijmen BJM, Willems van Dijk K, van 't Hof HB, van Gorp PJJ, van der Boom H, Breuer ML, Hofker MH, Havekes LM. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg158→Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. **J Biol Chem** 1996; 271: 30595-30602.

Jong MC, Dahlmans VEH, van Gorp PJJ, Breuer ML, Mol MJTM, van der Zee A, Frants RR, Hofker MH, Havekes LM. Both lipolysis and hepatic uptake of very low density lipoproteins are impaired in transgenic mice co-expressing human apolipoprotein E*3Leiden and human apolipoprotein C1. **Arterioscler Thromb Vasc Biol** 1996; 16: 934-940.

Van Vlijmen BJM, van 't Hof HB, Mol MJTM, van der Boom H, van der Zee A, Frants RR, Hofker MH, Havekes LM. Modulation of very low density lipoprotein production and clearance contributes to age and gender dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. **J Clin Invest** 1996; 97: 1184-1192.

Van Vlijmen B, van den Maagdenberg AMJM, Gijbels MJJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. **J Clin Invest** 1994; 93: 1403-1410.

Van den Maagdenberg AMJM, Hofker MH, Krimpenfort PJA, de Bruijn IG, van Vlijmen B, van der Boom H, Havekes LM, Frants RR. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. **J Biol Chem** 1993; 268: 10540-10545.

Atherosclerosis studies in APOE*3Leiden transgenic mice

van Dijk RA, Kleemann R, Schaapherder AF, van den Bogaardt A, Hedin U, Matic L, Lindeman JHN. Validating human and mouse tissues commonly used in atherosclerosis research with coronary and aortic reference tissue: similarities but profound differences in disease initiation and plaque stability. **JVS: Vascular Sci** 2023. doi.org/10.1016/j.jvssci.2023.100118.

van Broekhoven A, Krijnen PAJ, Fuijkschot WW, Morrison MC, Zethof IPA, van Wieringen WN, Smulders YM, Niessen HWM, Vonk ABA. Short-term LPS induces aortic valve thickening in ApoE*3Leiden mice. **Eur J Clin Invest** 2019; 49(7):e13121. doi: 10.1111/eci.13121.

Pouwer MG, Heinonen SE, Behrendt M, Andréasson AC, van Koppen A, Menke AL, Pieterman EJ, van den Hoek AM, Jukema JWJ, Leighton B, Jönsson- Rylander AC, Princen HMG. The APOE*3-Leiden.heterozygous glucokinase knockout mouse as novel translational disease model for type 2 diabetes, dyslipidemia and diabetic atherosclerosis. **J Diab Res** 2019; Article ID 9727952. doi.org/10.1155/2019/9727952. *

Fuijkschot WW, Morrison MC, Zethof IPA, Krijnen PAJ, Kleemann R, Niessen HWM, Smulders YM. LPS-induced systemic inflammation does not alter atherosclerotic plaque area or inflammation in APOE3*Leiden mice in the early phase up to 15 days. **Shock** 2017; Sep;50(3):360-365. doi: 10.1097/SHK.0000000000001026.

Zimmer M, Bista P, Benson EL, Lee DY, Liu F, Picarella D, Vega RB, Vu CB, Yeager M, Ding M, Liang G, Horton JD, Kleemann R, Kooistra T, Morrison MC, Wielinga PY, Milne JC, Jirousek MR, Nichols AJ. CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. **Hepatol Comm** 2017; 1(4):311-325. doi: 10.1002/hep4.1042. eCollection 2017 Jun. *

Salic K, Morrison MC, Verschuren L, Wielinga PY, Wu L, Kleemann R, Gjorstrup P, Kooistra T. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. **Atherosclerosis** 2016; 250:158-65. doi: 10.1016/j.atherosclerosis.2016.05.001.*

Morrison MC, Mulder P, Stavro PM, Suárez M, Arola-Arnal A, van Duyvenvoorde W, Kooistra T, Wielinga PY, Kleemann R. Replacement of dietary saturated fat by PUFA-rich pumpkin seed oil attenuates non-alcoholic fatty liver disease and atherosclerosis development, with additional health effects of virgin over refined oil. **PLoS One** 2015; 10:e0139196. doi: 10.1371/journal.pone.0139196. *

Morrison M, van der Heijden R, Heeringa P, Kaijzel E, Verschuren L, Blomhoff R, Kooistra T, Kleemann R. Epicatechin attenuates atherosclerosis and exerts anti-inflammatory effects on diet-induced human-CRP and NFkB in vivo. **Atherosclerosis** 2014; 233: 149-156., doi: 10.1016/j.atherosclerosis.2013.12.027.

Georgiadi A, Wang Y, Stienstra R, Tjeerdema N, Janssen A, Stalenhoef A, van der Vliet JA, de Roos A, Tamsma JT, Smit JW, Tan NS, Müller M, Rensen PC, Kersten S. Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development. **Arterioscler Thromb Vasc Biol** 2013; 33: 1529-1537.

Yakala GK, Wielinga PY, Suarez M, Bunschoten A, van Golde JM, Arola L, Keijer J, Kleemann R, Kooistra T, Heeringa P. Effects of chocolate supplementation on metabolic and cardiovascular parameters in ApoE3L mice fed a high-cholesterol atherogenic diet. **Mol Nutr Food Res** 2013; 57: 2039–2048.

Wong MC, van Diepen JA, Hu L, Guigas B, de Boer HC, van Puijvelde GH, Kuiper J, van Zonneveld AJ, Shoelson SE, Voshol PJ, Romijn JA, Havekes LM, Tamsma JT, Rensen PC, Hiemstra PS, Berbée JF. Hepatocyte-specific IKKβ expression aggravates atherosclerosis development in APOE*3-Leiden mice. **Atherosclerosis** 2012; 220: 362-368 .

Verschuren L, Radonjic M, Wielinga P, Kelder T, van Someren E, Kooistra T, van Ommen B, Kleemann R. Systems biology analysis unravels complementary action of combined rosuvastatin and ezetimibe therapy. **Pharmacogen Genom** 2012; 22: 837-45.

Kleemann R, Bureeva S, Perlina A, Kaput J, Verschuren L, Wielinga PY, Hurt-Camejo E, Nikolsky Y, van Ommen B, Kooistra T. A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis. **BMC Syst Biol** 2011; 5: 125-141*.

Van der Hoorn JWA, Lindén D, Lindahl U, Bekkers MEA, Voskuilen M, Nilsson R, Oscarsson J, Lindstedt EL, Princen HMG. Low dose of LXR agonist AZ876 reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels. **Brit J Pharmacol** 2011; 162; 1553-1563.*

Wielinga PY, Yakala GK, Heeringa P, Kleemann R, Kooistra T. Beneficial effects of alternate dietary regimen on liver

inflammation, atherosclerosis and renal activation. **PLOS One** 2011; 6: 1-9. e18432

Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY, Kooistra T. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. **Atherosclerosis** 2011; 218: 44– 52.

Verschuren L, Wielinga PY, van Duyvenvoorde W, Tijani S, Toet K, van Ommen B, Kooistra T, Kleemann R. A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C Reduces atherosclerosis in transgenic mice. **J Nutr** 2011; 141:863-869.

De Vries-van der Weij J, Toet K, Zadelaar S, Wielinga PY, Kleemann R, Rensen PCN, Kooistra T. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF- κ B activity and lowering of cholesterol. **Atherosclerosis** 2010; 213: 241-246.

Bietrix F, Lombardo E, Van Roomen CPAA, Ottenhoff R, Vos M, Rensen PCN, Verhoeven AJ, Aerts JM, Groen AK. Inhibition of glycosphingolipid synthesis induces a profound reduction of plasma cholesterol and inhibits atherosclerosis development in APOE*3Leiden and Low-density Lipoprotein Receptor α 1 mice. **Arterioscler Thromb Vasc Biol** 2010; 30: 931-937.

Pols TW, Bonta PI, Pires NM, Otermin I, Vos M, de Vries MR, van Eijk M, Roelofsen J, Havekes LM, Quax PH, van Kuilenburg AB, de Waard V, Pannekoek H, de Vries CJ. 6-Mercaptopurine inhibits atherosclerosis in apolipoprotein E*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. **Arterioscler Thromb Vasc Biol** 2010; 30: 1591-1597.

Den Boer MA, Westerterp M, de Vries-van der Weij J, Wang Y, Hu L, Espirito Santo SM, Kooistra T, Reiss P, Romijn JA, Havekes LM, Rensen PC. Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice. **Atherosclerosis** 2010; 210: 381-387.

Verschuren L, de Vries-van der Weij J, Zadelaar S, Kleemann R, Kooistra T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3-Leiden mice: time course and potential mechanisms. **J Lipid Res** 2009; 50: 301-311.

DeRuiter MC, Alkemade FE, Gittenberger-de Groot AC, Poelmann RE, Havekes LM, van Dijk KW. Maternal transmission of risk for atherosclerosis. **Curr Opin Lipidol** 2008; 19: 333-337. **Review.**

Van der Hoorn JWA, Kleemann R, Havekes LM, Kooistra T, Princen HMG, Jukema JW. Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3-Leiden transgenic mice. **J Hypertension** 2007; 25: 2454-2462. *

Kleemann R, Verschuren L, van Erk MJ et al. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. **Genome Biology** 2007; 8: R200, 1-16

Eefting D, Schepers A, De Vries MR, Pires NM, Grimbergen JM, Lagerweij T, Nagelkerken LM, Monraats PS, Jukema JW, van Bockel JH, Quax PH. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. **Atherosclerosis** 2007; 193: 335-342.

Schepers A, de Vries MR, van Leuven CJ, Grimbergen JM, Holers VM, Daha MR, van Bockel JH, Quax PH. Inhibition of complement component C3 reduces vein graft atherosclerosis in apolipoprotein E3-Leiden transgenic mice. **Circulation** 2006; 114: 2831-2838.

Zadelaar ASM, Boesten LSM, Jukema JW, van Vlijmen BJM, Kooistra T, Emeis JJ, Lundholm E, Camejo G, Havekes LM. Dual PPAR α /y agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic APOE*3-Leiden mice. **Arterioscler Thromb Vasc Biol** 2006; 26: 2560-2566. *

Kooistra T, Verschuren L, van der Weij J, Koenig W, Toet K, Princen HMG, Kleemann R. Fenofibrate reduces atherogenesis in APOE*3Leiden mice: evidence for multiple anti-atherogenic effects besides lowering plasma cholesterol. **Arterioscler Thromb Vasc Biol** 2006; 26: 2322-2330. *

Pires NM, Jukema JW, Daemen MJ, Quax PH. Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis? **Vascul Pharmacol** 2006; 44: 257-64.

Schepers A, Eefting D, Bonta PI, Grimbergen JM, deVries MR, vanWeel V, deVries CJ, Egashira K, vanBockel, JH, Quax PHA. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. **Arterioscler Thromb Vasc Biol** 2006; 26: 2063-2069.

Schepers A, PiresNM, Eefting D, de Vries MR, van Bockel JH, Quax PH. Short-term dexamethasone treatment inhibits vein graft thickening in hypercholesterolemic ApoE3Leiden transgenic mice. **J Vasc Surg** **2006**;43:809-815.

vanWeel V, deVries M, Voshol PJ, Verloop RE, Eilers PHC, vanHinsbergh VWM, vanBockel H, Quax PHA.. Hypercholesterolemia reduces collateral artery growth more dominantly than hyperglycemia or insulin resistance in mice. **Arterioscler Thromb Vasc Biol** **2006**; 26: 1383-1390.

Trion A, deMaat M, Jukema W, Maas A, Offerman E, Havekes L, Szalai A, vanderLaarse A, Princen H, Emeis J. Anti-atherosclerotic effect of amlolipine, alone and in combination with atorvastatin, in ApoE*3-Leiden/hCRP transgenic mice. **J Cardiovasc Pharmacol** **2006**; 47:89-95. *

Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR, Zwinderman AH, de Maat MP, Doevendans PA, de Winter RJ, Tio RA, Waltenberger J, 't Hart LM, Frants RR, Quax PH, van Vlijmen BJ, Havekes LM, van der Laarse A, van der Wall EE, Jukema JW. Tumor necrosis factor-alpha plays an important role in restenosis development. **FASEB J** **2005** ; 19: 1998-2004.

Pires NM, Schepers A, van der Hoeven ML, Boesten LS, de Vries MR, Jukema JW, Quax PH. Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries. **Cardiovasc Res** **2005**; 68: 415-424.

Trion A, deMaat MPM, Jukema JW, vanderLaarse A, Maas MC, Offerman EH, Havekes LM, Szalai AJ, Princen HMG, Emeis JJ. No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-Leiden/human C-reactive protein transgenic mice. **Arterioscler Thromb Vasc Biol** **2005**; 25:1635-1640. *

Pires NM, van der Hoeven ML, de Vries MR, Havekes LM, van Vlijmen BJ, Hennink WJ, Quax PH, Jukema JW. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff. **Biomaterials** **2005**; 26: 5386-5394.

Boesten LS, Zadelaar AS, van Nieuwkoop A, Gijbels MJ, de Winther MP, Havekes LM, van Vlijmen BJ. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice. **Cardiovasc Res** **2005**; 66: 179-185

Verschuren L, Kleemann R, Offerman EH, Szalai AJ, Emeis JJ, Princen HMG, Kooistra T. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice. **Arterioscler Thromb Vasc Biol** **2005**; 25: 161-167.

Lardenoye JHP, deVries MR, Deckers M, vanLent N, Hanemaaijer R, vanBockel JH, Quax PHA. Inhibition of intimal hyperplasia by the tetracycline derived MMP inhibitor doxycycline in vein graft disease *in vitro* and *in vivo*. **EuroInterv** **2005**; 1: 236-243.

Espirito Santo SMS, vanVlijmen BJM, vanDuyvenvoorde W, Offerman EH, Havekes LM, Arnault I, Auger J, Princen HMG. Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice. **Atherosclerosis** **2004**; 177: 291-297.

Kleemann R, Princen HMG, Emeis JJ, Jukema JW Fontijn RD, Horrevoets AJG, Kooistra T, Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in apoE*3Leiden transgenic mice: Evidence for anti-inflammatory effects of rosuvastatin. **Circulation** **2003**; 108: 1368-1374. *

Delsing DJM, Jukema JW, van de Wiel MA, Emeis JJ, van der Laarse A, Havekes LM, Princen HMG. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. **J Cardiovasc Pharmacol** **2003**; 42: 63-70. *

Van de Poll SWE, Delsing DJM, Jukema JW, Princen HMG, Havekes LM, Puppels GJ, Van der Laarse A. Effects of amlodipine, atorvastatin and the combination of both on advanced atherosclerotic plaque in ApoE*3 Leiden transgenic mice. **J Mol Cell Cardiol** **2003**; 35: 109-118. *

Lardenoye JHP, deVries MR, Löwik CWGM, Xu Q, Dhore CR, Cleutjens JPM, vanHinsbergh VWM, vanBockel JH, Quax PHA. Accelerated atherosclerosis and calcification in vein grafts a study in APOE*3 Leiden transgenic mice. **Circ Res** **2002**; 91: 577-584.

Lardenoye JHP, deVries MR, Grimbergen JM, Havekes LM, Knaapen MWM, Kockx MM, vanHinsbergh VWM, vanBockel JH, Quax PHA. Inhibition of accelerated atherosclerosis in vein grafts by placement of external stent in



ApoE*3-Leiden transgenic mice. **Arterioscler Thromb Vasc Biol** 2002; 22: 1433-1438.

Rezaee F, Gijbels MJ, Offerman EH, vanderLinden M, deMaat MPM, Verheijen JH. Overexpression of fibrinogen in ApoE*3-Leiden transgenic mice does not influence the progression of diet-induced atherosclerosis. **Thromb Haemost** 2002; 88: 329-334.

Van de Poll SWE, Delsing DJM, Jukema JW, Princen HMG, Havekes LM, Puppels GJ, Van der Laarse A. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in ApoE*3 Leiden transgenic mice. **Atherosclerosis** 2002; 164: 65-71. *

Van de Poll SWE, Römer TJ, Volger OL, Delsing DJM, Bakker Schut TC, Princen HMG, Havekes LM, Jukema JW, Puppels GJ, Van der Laarse A. Raman spectroscopic monitoring of the effects of diet and lipid lowering therapy on atherosclerotic plaque development. **Arterioscler Thromb Vasc Biol** 2001; 21: 1630-1635. *

Volger OL, Mensink RP, Plat J, Hornstra G, Havekes LM, Princen HMG. Dietary vegetable oil and wood-derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3Leiden transgenic mice. **Atherosclerosis** 2001; 157: 375-381. *

van Vlijmen BJM, Gerritsen G, Franken AL, Boesten LSM, Kockx M, Gijbels MJ, Vierboom MP, van Eck M, van de Water B, van Berkel TJC, Havekes LM. Macrophage p53 deficiency leads to enhanced atherosclerosis on APOE*3-Leiden transgenic mice. **Circ Res** 2001; 88: 780-786.

Delsing DJM, Offerman EH, van Duyvenvoorde W, van der Boom H, de Wit ECM, Gijbels MJJ, Van der Laarse A, Jukema JW, Havekes LM, Princen HMG. The acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in apoE*3Leiden mice. **Circulation** 2001; 103:1778-1786. *

Lardenoye JHP, Delsing DJM, de Vries MR, Deckers MML, Princen HMG, Havekes LM, van Hinsbergh VWM, van Bockel JH, Quax PHA. Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in apoE*3Leiden transgenic mice. **Circ Res** 2000; 87: 248-253.

Quax PHA, Lardenoye JWHP, Havekes LM, Princen HMG. Transgenic models for normal atherosclerotic plaque formation and the accelerated atherosclerosis and restenosis after vascular injury. **Eur Pharmaceut Contract** 2000; 44-46.

Van Eck M, Herijgers N, Van Dijk KW, Havekes LM, Hofker MH, Groot PH, Van Berkel TJ. Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg158-->Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice. **Arterioscler Thromb Vasc Biol** 2000; 20: 119-127.

De Winther MPJ, Gijbels MJJ, Willems van Dijk K, van Gorp PJJ, Suzuki H, Kodama T, Frants RR, Havekes LM, Hofker MH. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. **Atherosclerosis** 1999; 144: 315-321.

Gijbels MJJ, van der Cammen M, van der Laan L, Emeis JJ, Havekes LM, Hofker MH, Kraal G. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. **Atherosclerosis** 1999; 143: 15-25.

Lutgens E, Daemen M, Kockx M, Doevendans P, Hofker MH, Havekes LM, Wellens H, de Muinck E. Lesion development and cell turnover in the APOE*3Leiden mouse. **Circulation** 1999; 99: 276-283.

Hofker MH, van Vlijmen BJM, Havekes LM. Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. **Atherosclerosis** 1998; 137: 1-11. **Review**

Leppanen P, Luoma JS, Hofker MH, Havekes LM, Yla-Herttuala S. Characterization of atherosclerotic lesions in apolipoprotein E3-Leiden transgenic mice. **Atherosclerosis** 1998; 136: 147-152.

Groot PHE, van Vlijmen BJM, Benson GM, Hofker MH, Schifflers R, Vidgeon-Hart M, Havekes LM. Quantitative assessment of aortic atherosclerosis in apoE3Leiden transgenic mice and its relationship to serum cholesterol exposure. **Arterioscler Thromb Vasc Biol** 1996; 16: 926-933. *

Van Vlijmen B, van den Maagdenberg AMJM, Gijbels MJJ, van der Boom H, HogenEsch H, Frants RR, Hofker MH, Havekes LM. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. **J Clin Invest** 1994; 93: 1403-1410.

Vascular and cognitive function, stroke, myocardial infarction

Seidel F, Morrison MC, Arnoldussen I, Verweij V, Ebert S, Attema J, de Ruiter C, van Duyvenvoorde W, Snabel J, Geenen B, Franco A, Gart E, Bernhagen J, Wiesmann M, Kleemann R, Kiliaan AJ. Partial removal of visceral epididymal white adipose tissue in obese Ldlr^{-/-}. Leiden mice impacts adipokine secretion, plasma free fatty acids, and improves cerebrovascular health. **Plos One** **2025**; 20: e0333024. doi.org/10.1371/journal.pone.0333024.

Custers E, Vreeken D, Kleemann R, Kessels RPC, Tijman op Smeijers E, Hog Mortensen, Morrison MC, Gart E, Wiesmann M, Hazebroek EJ, Kiliaan AJ. Sustained improvement of cognition, mood and plasma markers 3 years after metabolic bariatric surgery. The BARICO Study. **Obes Surg** **2025**; 35: 3888-3900. doi.org/10.1007/s11695-025-08198-5.

Jia R, Solé-Guardia G, Verweij V, Snabel JM, Geenen B, Man Tuladhar A, Kleemann R, Kiliaan AJ, Wiesmann M. Identification and characterization of a translational mouse model for blood-brain barrier leakage in cerebral small vessel disease. **Int J Mol Sci** **2025**; 26: 6706. doi.org/10.3390/ijms26146706.

Bar A, Berkowicz P, Kurpińska A, Mohaissen T, Karaś A, Kaczara P, Suraj-Prażmowska J, Strenak M, Marczyk B, Malinowska A, Kij A, Jasztal A, Czyżyńska-Cichoń I, Pieterman E, Princen HMG, Wiśniewski JR, Chlopicki S. Effects of life-long hyperlipidaemia on age-dependent development of endothelial dysfunction in humanised dyslipidaemic mice. **GeroScience** **2025**; doi.org/10.1007/s11357-025-01578-w.

Kij A, Kieronska-Rudek A, Bar A, Czyżyńska-Cichoń I, Strus M, Kozien L, Wiecek G, Zeber-Lubecka N, Kulecka M, Kwiatkowski G, Przyborowski K, Mohaissen T, Strenak M, Buczek E, Zakrzewska A, Proniewski B, Kus K, Franczyk-Zarow M, Kostogrys RB, Pieterman EJ, Princen HMG, Chlopicki S. Low phylloquinone intake deteriorates endothelial function in normolipidemic and dyslipidaemic mice. **J Nutr Biochem** **2025**; 140:109867. doi.org/10.1016/j.jnutbio.2025.109867.

Seidel F, Morrison MC, Arnoldussen I, Verweij V, Attema J, de Ruiter C, van Duyvenvoorde W, Snabel J, Geenen B, Franco A, Wiesmann M, Kleemann R, Kiliaan AJ. Obesity accelerates age-related memory deficits and alters white matter tract integrity in Ldlr^{-/-}. Leiden mice. **Brain Behav Immun Health** **2025**; 45:100991. doi.org/10.1016/j.bbih.2025.100991.

Kaufmann LK, Custers E, Vreeken D, Snabel J, Morrison MC, Kleemann R, Wiesmann M, Hazebroek EJ, Aarts E, Kiliaan AJ. Surgery-induced reduction in inflammation relates to improved neural inhibitory control in obesity. **Brain Behav Immun** **2025**; 129: 829-838. doi.org/10.1016/j.bbi.2025.07.012.

Seidel F, Vreeken D, Custers E, Wiesmann M, Özsezen S, van Duyvenvoorde W, Caspers M, Menke A, Morrison MC, Verschuren L, Duering M, Hazebroek EJ, Kiliaan AJ, Kleemann R. Metabolic dysfunction-associated steatotic liver disease is associated with effects on cerebral perfusion and white matter integrity. **Heliyon** **2024**; 10: e38516. doi: 10.1016/j.heliyon.2024.e38516.

Kaufmann LK, Custers E, Vreeken D, Snabel J, Morrison MC, Kleemann R, Wiesmann M, Hazebroek EJ, Aarts E, Kiliaan AJ. Additive effects of depression and obesity on neural correlates of inhibitory control. **J Affect Disord** **2024**; 362: 174-185. doi: 10.1016/j.jad.2024.06.093.

Hogenelst K, Özsezen S, Kleemann R, Verschuren L, Stuldreher I, Bottenheft C, van Erp J, Brouwer AM. Seven robust and easy to obtain biomarkers to measure acute stress. **Brain Behav Immun Health** **2024**; 38:100789. doi: 10.1016/j.bbih.2024.100789.

Custers E, Vreeken D, Kleemann R, Kessels RPC, Duering M, Brouwer J, Aufenacker TJ, Witteman BPL, Snabel J, Gart E, Mutsaerts HJMM, Wiesmann M, Hazebroek EJ, Kiliaan AJ. Long-term brain structure and cognition following bariatric surgery. **JAMA Netw Open** **2024**; 7: e2355380. doi: 10.1001/jamanetworkopen.2023.55380.

Vreeken D, Seidel F, de la Roij G, Vening W, den Hengst WA, Verschuren L, Özsezen S, Kessels RPC, Duering M, Mutsaerts HJMM, Kleemann R, Wiesmann M, Hazebroek EJ, Kiliaan AJ. Impact of white adipose tissue on brain structure, perfusion, and cognitive function in patients with severe obesity_ The BARICO Study. **Neurology** **2023**; 100: e703-e718. doi:10.1212/WNL.00000000000201538.

Lohkamp KJ, van den Hoek AM, Solé-Guardia G, Lisovets M, Alves Hoffmann T, Velanaki K, Geenen B, Verweij V, Morrison MC, Kleemann R, Wiesmann M, Kiliaan AJ. The preventive effect of exercise and oral branched-chain amino acid supplementation on obesity-induced brain changes in Ldlr^{-/-}. Leiden mice. **Nutrients** **2023**; 15, 1716. doi.org/10.3390/nu15071716.

Seidel F, Fluiter K, Kleemann R, Worms N, van Nieuwkoop A, Caspers MPM, Grigoriadis N, Kiliaan AJ, Baas F, Michailidou I, Morrison MC. Ldlr^{-/-}.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody. **Front Cell Neurosci** **2023**; 17:1205261. doi: 10.3389/fncel.2023.1205261.

Mohanta SK, Peng L, Li Y, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed BR, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, Klupp BG, Megens RTA, Steffens S, Pelisek J, Eckstein HH, **Kleemann R**, Habenicht L, Mallat Z, Michel JB, Bernhagen J, Dichgans M, D'Agostino G, Guzik TJ, Olofsson PS, Yin C, Weber C, Lembo G, Carnevale D, Habenicht AJR. Neuroimmune cardiovascular interfaces control atherosclerosis. **Nature** **2022**; 605: 152-159. doi.org/10.1038/s41586-022-04673-6.

Arnoldussen IAC, Morrison MC, Wiesmann M, van Diepen JA, Worms N, Voskuilen M, Verweij V, Geenen B, Pujol Gualdo N, van der Logt L, Gross G, Kleemann R, Kiliaan AJ. Milk fat globule membrane attenuates high fat diet-induced neuropathological changes in obese Ldlr^{-/-}.Leiden mice. **Int J Obes** **2022**; 1-8. doi.org/10.1038/s41366-021-00998-w.

Davies R, van Diepen JA, Brink LR, Bijlsma S, McVey Neufeld KA, Cryan JF, O'Mahony SM, Bobeldijk I, Gross G. Lipidome analysis in brain and peripheral plasma following milk fat globule membrane supplementation in rodents. **Mol Nutr Food Res** **2022**; 2200177. doi: 10.1002/mnfr.202200177.

Schlunk F, Fischer P, Princen HMG, Rex A, Prinz V, Foddiss M, Lütjohann D, Laufs U, Endres M. No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. **Behav Brain Res** **2021**; 396: 112875 (1-7). doi.org/10.1016/j.bbr.2020.112875.

Bar A, Kieronska-Rudeka A, Proniewska B, Suraj-Prażmowska J, Czamara K, Marczyk B, Matyjaszczyk-Gwarda K, Jasztala A, Kuśa E, Majka Z, Kaczor A, Kurpińska A, Walczak M, Pieterman E, Princen HMG, Chlopicki S. In vivo MRI-based detection of heterogeneous endothelial response in thoracic and abdominal aorta to short-term high-fat diet ascribed to differences in perivascular adipose tissue in mice. **J Am Heart Assoc** **2020**; 9: e016929. doi: 10.1161/JAHA.120.016929.

Schlunk F, Fischer P, Princen HMG, Rex A, Prinz V, Foddiss M, Lütjohann D, Laufs U, Endres M. Effects of inhibition or deletion of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) on intracerebral hemorrhage volumes in mice. **Stroke** **2020**; 51: e297–e298. doi: 10.1161/STROKEAHA.120.030087.

Tengeler AC, Gart E, Wiesmann M, Arnoldussen IAC, van Duyvenvoorde W, Hoogstad M, Dederen PJ, Verweij V, Geenen B, Kozicz T, Kleemann R, Morrison MC, Kiliaan AJ. Propionic acid and not caproic acid, attenuates non-alcoholic steatohepatitis and improves (cerebro) vascular functions in obese Ldlr^{-/-}.Leiden mice. **FASEB J** **2020**; 34: 9575-9593. doi: 10.1096/fj.20200455R.

Verschuren L, Wielinga PY, Kelder T, Radonjic M, Salic K, Kleemann R, van Ommen B, Kooistra T. A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. **BMC Med Genomics** **2014**;7: 35. doi: 10.1186/1755-8794-7-35.

Louwe MC, Karper JC, de Vries MR, Nossent AY, Bastiaansen AJ, van der Hoorn JW, Willems van Dijk K, Rensen PC, Steendijk P, Smit JW, Quax PH. RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice. **Int J Cardiol.** **2014** Aug 3. pii: S0167-5273(14)01296-0. doi: 10.1016/j.ijcard.2014.07.086.

Louwe MC, van der Hoorn JW, van den Berg SA, Jukema JW, Romijn JA, van Dijk KW, Rensen PC, Smit JW, Steendijk P. Gender-dependent effects of high-fat lard diet on cardiac function in C57Bl/6J mice. **Appl Physiol Nutr Metab.** **2012** Apr;37(2):214-24.

Van der Hoorn JWA, Jukema JW, Bekkers ME, Princen HMG, Corda S, Emeis JJ, Steendijk P. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE*3-Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). **Crit Care Med** **2008**; 38: 2576-2582. *

MASLD, MASH and liver fibrosis

van Son KC, de Jong JCBC, Özsezen S, Caspers MPM, Augustijn QJJ, Snabel J, Galenkamp H, Hamer HM, van Dijk AM, van Koppen A, Mak AL, van den Born BJ, Nieuwdorp M, Drenth JPH, Gluud LL, Tushuizen ME, Hanemaaijer R, Verschuren L, Holleboom AG. Prognostic value of the TLM3 biomarker panel for early fibrosis development in MASLD



within general population. **Liver Int** **2025**; 45: e70169. doi.org/10.1111/liv.70169.

Gonzalez Hernandez MA, Venhorst J, Verschuren L, Toet K, Caspers MPM, Morrison MC, Coornaert B, van Westen GJP, Hanemaaijer R. Improved translational relevance of in vitro fibrosis models by integrating IOX2-mediated hypoxia-mimicking pathways. **Biomedicines** **2025**; 13:1448. doi.org/10.3390/biomedicines13061448.

Inia JA, Morrison MC, van Koppen A, Gart E, Caspers MPM, Menke AL, Worms N, Kleemann R, Verschuren L, Jukema JW, Princen HMG, Hanemaaijer R, van den Hoek AM. Fibrogenic gene signature as early prediction for the efficacy of pharmacological interventions for MASH-related fibrosis. **FASEB J** **2025**; 39: e70735. doi.org/10.1096/fj.202500718R.

Inia JA, Attema J de Ruiter C, Menke AL, Caspers MPM, Verschuren L, Wilson M, Arlantino A, Brightbill HD, Jukema JW, van den Hoek AM, Princen HMG, Chen MZ, Morrison MC. Therapeutic effects of FGF21 mimetic bFGF1 on MASH and atherosclerosis in Ldlr^{-/-}.Leiden mice. **FASEB J** **2024**; 38: e70087. doi.org/10.1096/fj.202401397R. *

Verschuren L, Mak AL, van Koppen A, Özsezen S, DiFrancesco S, Caspers MPM, Snabel J, van der Meer D, van Dijk AM, Rashu EB, Nabilou P, Werge MP, van Son K, Kleemann R, Kiliaan AJ, Hazebroek EJ, Boonstra A, Brouwer WP, Doukas M, Gupta S, Kluff C, Nieuwdorp M, Verheij J, Gluud LL, Holleboom AG, Tushuizen ME, Hanemaaijer R. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. **Nat Commun** **2024**; 15: 4564. doi: 10.1038/s41467-024-48956-0. *

González Hernández MA, Verschuren L, Caspers MPM, Morrison MC, Venhorst J, van den Berg JT, Coornaert B, Hanemaaijer R, van Westen GJP. Identifying patient subgroups in MASLD and MASH-associated fibrosis: molecular profiles and implications for drug development. **Sci Rep** **2024**; 14: 23362. doi: 10.1038/s41598-024-74098-w. *

Inia JA, de Jong JCBC, Keijzer N, Menke AL, Princen HMG, Jukema JW, van den Hoek AM. Effects of repeated weight cycling on non-alcoholic steatohepatitis in diet-induced obese mice. **FASEB J** **2024**; 38 : e23579. doi.org/10.1096/fj.202400167R.

Seidel F, Vreeken D, Custers E, Wiesmann M, Özsezen S, van Duyvenvoorde W, Caspers M, Menke A, Morrison MC, Verschuren L, Duering M, Hazebroek EJ, Kiliaan AJ, Kleemann R. Metabolic dysfunction-associated steatotic liver disease is associated with effects on cerebral perfusion and white matter integrity. **Heliyon** **2024**; 10: e38516. doi: 10.1016/j.heliyon.2024.e38516.

Venhorst J, Hanemaaijer R, Dulos R, Caspers MPM, Toet K, Attema J, de Ruiter C, Kalkman G, Rouhani Rankouhi T, de Jong JCBC, Verschuren L. Integrating text mining with network models for successful target identification: in vitro validation in MASH-induced liver fibrosis. **Front Pharmacol** **2024**; 15: e1442752. doi/10.3389/fphar.2024.1442752.

Inia JA, Stokman G, Pieterman EJ, Morrison MC, Worms N, Verschuren L, Caspers MPM, Menke AL, Petitjean M, Petitjean L, Chen L, Jukema JW, Princen HMG, van den Hoek AM. Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr^{-/-}.Leiden mice. **Int J Mol Sci** **2023**; 24: 8494. doi.org/10.3390/ijms24108494.

Inia JA, Stokman G, Pieterman EJ, Morrison MC, Menke AL, Verschuren L, Caspers MPM, Giera M, Jukema JW, van den Hoek AM, Princen HMG. Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in APOE*3-Leiden mice by reducing hepatic inflammation. **Int J Mol Sci** **2023**; 24: 7818. doi.org/10.3390/ijms24097818.

Gart E, van Duyvenvoorde W, Snabel JM, de Ruiter C, Attema J, Caspers MPM, Lek S, van Heuven BJ, Speksnijder AGCL, Giera M, Menke A, Salic K, Bence KK, Tesz GJ, Keijzer J, Kleemann R, Morrison MC. Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr^{-/-}.Leiden mice. **Heliyon** **2023**; 9: e13985. doi.org/10.1016/j.heliyon.2023.e13985. *

Gayban AJB, Souza LAC, Cooper SG, Regalado E, Kleemann R, Feng Earley Y. (Pro)Renin receptor antagonism attenuates high-fat-diet-induced hepatic steatosis. **Biomolecules** **2023**; 13: 142. doi: 10.3390/biom13010142.

Seidel F, Kleemann R, van Duyvenvoorde W, van Trigt N, Keijzer N, van der Kooij S, van Kooten C, Verschuren L, Menke A, Kiliaan AJ, Winter J, Hughes TR, Morgan BP, Baas F, Fluiter K, Morrison MC. Therapeutic intervention with anti-complement component 5 antibody does not reduce NASH but does attenuate atherosclerosis and MIF concentrations in Ldlr^{-/-}.Leiden mice. **Int J Mol Sci**. **2022**; 23(18):10736. doi: 10.3390/ijms231810736.

Van Loy T, De Jonghe S, Castermans K, Dheedene W, Stoop R, Verschuren L, Versele M, Chaltin P, Luttun A, Schols D. Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model. **Cell Mol Life Sci** **2022**; 79(6): 293. doi: 10.1007/s00018-022-04317-y. *

van den Hoek AM, Özsezen S, Caspers MPM, van Koppen A, Hanemaaijer R, Verschuren L. Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis. **Int J Mol Sci** **2022**; 23(15): 8229. doi.org/10.3390/ijms23158229.

Gart E, Salic K, Morrison MC, Giera M, Attema J, de Ruiter C, Caspers M, Schuren F, Bobeldijk-Pastorova I, Heer M, Qin Y, Kleemann R. The human milk oligosaccharide 2'-fucosyllactose alleviates liver steatosis, ER stress and insulin resistance by reducing hepatic diacylglycerols and improved gut permeability in obese Ldlr-/-Leiden mice. **Front Nutr** **2022**; 9: 904740. doi: 10.3389/fnut.2022.904740. *

Gart E, van Duyvenvoorde W, Caspers MPM, van Trigt N, Snabel J, Menke A, Keijer J, Salic K, Morrison MC, Kleemann R. Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr-/-Leiden mice with manifest obesity-associated NASH. **FASEB J** **2022**; 36(8): e22435. doi: 10.1096/fj.202200111R.

Morrison MC, Gart E, Duyvenvoorde WV, Snabel J, Nielsen MJ, Leeming DJ, Menke A, Kleemann R. Heat-Inactivated Akkermansia muciniphila Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr-/-Leiden Mice. **Int J Mol Sci** **2022**; 23(4): 2325. doi: 10.3390/ijms23042325. *

Martínez-Arranz I, Bruzzone C, Nouredin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, **Morrison MC, Kleemann R**, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. **Hepatology** **2022**; 76 (4): 1124-1134. doi: 10.1002/hep.32427

Gart E, Salic K, Morrison MC, Caspers M, van Duyvenvoorde W, Heijink M, Giera M, Bobeldijk-Pastorova I, Keijer J, Storsve AB, Hals PA, Kleemann R. Krill Oil Treatment Increases Distinct PUFAs and Oxylipins in Adipose Tissue and Liver and Attenuates Obesity-Associated Inflammation via Direct and Indirect Mechanisms. **Nutrients** **2021**; 13(8):2836. doi: 10.3390/nu13082836. *

van den Hoek AM, de Jong JCBC, Worms N, van Nieuwkoop A, Voskuilen M, Menke AL, Lek S, Caspers MPM, Verschuren L, Kleemann R. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. **Metabolism** **2021**; 124:154873. doi: 10.1016/j.metabol.2021.154873.

Gart E, van Duyvenvoorde W, Toet K, Caspers MPM, Verschuren L, Nielsen MJ, Leeming DJ, Souto Lima E, Menke A, Hanemaaijer R, Keijer J, Salic K, Kleemann R, Morrison MC. Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF- β Signaling Pathways in Human Hepatic Stellate Cells. **Biomedicine** **2021**; 9(12):1954. doi: 10.3390/biomedicine9121954.

Mueller AM, Kleemann R, Gart E, van Duyvenvoorde W, Verschuren L, Caspers M, Menke A, Krömmelbein N, Salic K, Burmeister Y, Seilheimer B, Morrison MC. Cholesterol accumulation as a driver of hepatic inflammation under translational dietary conditions can be attenuated by a multicomponent medicine. **Front Endocrinol** **2021**; 12: 601160. doi: 10.3389/fendo.2021.601160 *

Álvarez-Amor L, Luque Sierra A, Cárdenas A, López-Bermudo L, López-Beas J, Andújar E, Pérez-Alegre M, Gallego-Durán R, Varela LM, Martín-Montalvo A, Berná G, Rojas A, Robles-Frías MJ, Hmadcha A, Romero-Gómez M, Kleemann R, Martín F. Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr-/-Leiden mice without attenuation of steatohepatitis. **Sci Rep** **2021**; 11: 8250. doi.org/10.1038/s41598-021-87761-3.

van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men. **Sci Rep** **2021**; 11: 5050. doi.org/10.1038/s41598-021-83974-8.

van den Hoek AM, Verschuren L, Worms N, van Nieuwkoop A, de Ruiter C, Attema J, Menke AL, Caspers MPM, Radhakrishnan S, Salic K, Kleemann R. A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology. **Cells** **2020**; 9(9): E2014. doi: 10.3390/cells9092014.

Tengeler AC, Gart E, Wiesmann M, Arnoldussen IAC, van Duyvenvoorde W, Hoogstad M, Dederen PJ, Verweij V, Geenen B, Kozicz T, Kleemann R, Morrison MC, Kiliaan AJ. Propionic acid and not caproic acid, attenuates non-



alcoholic steatohepatitis and improves (cerebro) vascular functions in obese *Ldlr*^{-/-}.Leiden mice. **FASEB J** **2020**; 34: 9575-9593. doi: 10.1096/fj.202000455R.

Stokman G, van den Hoek AM, Denker Thorbekk D, Pieterman EJ, Veidal SS, Basta B, Iruarrizaga-Lejarreta M, van der Hoorn JW, Verschuren L, Berbée JFP, Rensen PCN, Skjaeret T, Alonso C, Feigh M, Kastelein JJP, Friedman SL, Princen HMG, Fraser DA. Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative. **Liver Int** **2020**; 40: 2860-2876. doi: 10.1111/liv.14643. *

van den Hoek AM, Pieterman EJ, van der Hoorn JW, Iruarrizaga-Lejarreta M, Alonso C, Verschuren L, Skjæret T, Princen HMG, Fraser DA. Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity and fibrosis in mice. **Hepatol Comm** **2020**; 4: 193-207. doi:10.1002/hep4.1453 *

Salic K, Gart E, Seidel F, Verschuren L, Caspers M, van Duyvenvoorde W, Wong KE, Keijer J, Bobeldijk-Pastorova I, Wielinga PY, Kleemann R. Combined treatment with L-carnitine and nicotinamide riboside improves hepatic metabolism and attenuates obesity and liver steatosis. **Int J Mol Sci** **2019**; 20(18). pii: E4359. doi: 10.3390/ijms20184359.

Salic K, Kleemann R, Wilkins-Port C, McNulty J, Verschuren L, Palmer M. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of nonalcoholic steatohepatitis in *Ldlr*^{-/-}.Leiden mice. **PLoS One** **2019**; 14(6): e0218459. doi.org/10.1371/journal.pone.0218459. eCollection 2019. *

Jacobs SAH, Gart E, Vreeken D, Franx BAA, Wekking L, Verweij VGM, Worms N, Schoemaker MH, Gross G, Morrison MC, Kleemann R, Arnoldussen IAC, Kiliaan AJ. Sex-specific differences in fat storage, development of non-alcoholic fatty liver disease and brain structure in juvenile HFD-induced obese *Ldlr*^{-/-}.Leiden mice. **Nutrients** **2019**; 11: 1861; doi:10.3390/nu11081861.

Abe N, Kato S, Tsuchida T, Sugimoto K, Saito R, Verschuren L, Kleemann R, Oka K. Longitudinal characterization of diet-induced genetic murine models of non-alcoholic steatohepatitis with metabolic, histological, and transcriptomic hallmarks of human patients. **Biol Open** **2019**; 1; 8(5). pii: bio041251. doi: 10.1242/bio.041251. *

Pouwer MG, Heinonen SE, Behrendt M, Andréasson AC, van Koppen A, Menke AL, Pieterman EJ, van den Hoek AM, Jukema JWJ, Leighton B, Jönsson- Rylander AC, Princen HMG. The APOE*3-Leiden.heterozygous glucokinase knockout mouse as novel translational disease model for type 2 diabetes, dyslipidemia and diabetic atherosclerosis. **J Diab Res** **2019**; Article ID 9727952. doi.org/10.1155/2019/9727952 *

Gart E, Souto Lima E, Schuren F, de Ruiter CGF, Attema J, Verschuren L, Keijer J, Salic K, Morrison MC, Kleemann R. Diet-independent correlations between bacteria and dysfunction of gut, adipose tissue, and liver: A comprehensive microbiota analysis in feces and mucosa of the ileum and colon in obese mice with NAFLD. **Int J Mol Sci** **2019**; 20: 1. pii.: E1 doi:10.3390/ijms200100.

Morrison MC, Verschuren L, Salic K, Verheij J, Menke A, Wielinga PY, Iruarrizaga-Lejarreta M, Gole L, Yu WM, Turner S, Caspers MPM, Martínez-Arranz I, Pieterman E, Stoop R, van Koppen A, van den Hoek AM, Mato JM, Hanemaaijer R, Alonso C, Kleemann R. Obeticholic acid modulates serum metabolites and gene signatures characteristic of human NASH and attenuates inflammation and fibrosis progression in *Ldlr*^{-/-}.Leiden mice. **Hepatol Commun** **2018**. DOI 10.1002/hep4.1270. eCollection 2018 Sept.

Morrison MC, Kleemann R, van Koppen A, Hanemaaijer R, Verschuren L. Key inflammatory processes in human NASH are reflected in *Ldlr*^{-/-}.Leiden mice: a translational gene profiling study. **Front Physiol** **2018** Feb 23;9:132. doi: 10.3389/fphys.2018.00132. eCollection 2018.

van Koppen A, Verschuren L, van den Hoek AM, Verheij J, Morrison MC, Li K, Nagabukuro H, Costessi A, Caspers MPM, van den Broek TJ, Sagartz J, Kluit C, Beysen C, Emson C, van Gool AJ, Goldschmeding R, Stoop R, Bobeldijk-Pastorova I, Turner SM, Hanauer G, Hanemaaijer R. Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model. **Cell Mol Gastroenterol Hepatol** **2017** Oct 14;5(1):83-98.e10. doi: 10.1016/j.jcmgh.2017.10.001. eCollection 2018.

Schoemaker MH, Kleemann R, Morrison MC, Verheij J, Salic K, van Tol EAF, Kooistra T, Wielinga PY. A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in *LDLr*^{-/-}.Leiden mice. **PLoS One** **2017**; 12: e0180648. doi: 10.1371/journal.pone.0180648. *

Zimmer M, Bista P, Benson EL, Lee DY, Liu F, Picarella D, Vega RB, Vu CB, Yeager M, Ding M, Liang G, Horton JD, Kleemann R, Kooistra T, Morrison MC, Wielinga PY, Milne JC, Jirousek MR, Nichols AJ. CAT-2003: A novel sterol



regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. **Hepatol Commun.** **2017**;1(4):311-325. doi: 10.1002/hep4.1042. *

Mulder P, van den Hoek AM, Kleemann R. The CCR2 inhibitor propagermanium attenuates diet-induced insulin resistance, adipose tissue inflammation and non-alcoholic steatohepatitis. **PLoS One** **2017**; 12: e0169740. doi: 10.1371/journal.pone.0169740.

Mulder P, Morrison MC, Verschuren L, Liang W, van Bockel JH, Kooistra T, Wielinga PY, Kleemann R. Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLR-deficient mice. **Sci Rep** **2016**; 6: 31542. doi: 10.1038/srep31542

Morrison MC, Mulder P, Salic K, Verheij J, Liang W, van Duyvenvoorde W, Menke A, Kooistra T, Kleemann R, Wielinga PY. Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis (NASH) and hepatic fibrosis in LDLR^{-/-}-Leiden mice. **Int J Obes (Lond)** **2016**; 40: 1416-1423. doi: 10.1038/ijo.2016.74.

Liang W, Verschuren L, Mulder P, van der Hoorn JW, Verheij J, van Dam AD, Boon MR, Princen HM, Havekes LM, Kleemann R, van den Hoek AM. Salsalate attenuates diet induced non-alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. **Br J Pharmacol** **2015**; 172: 5293-5305. doi: 10.1111/bph.13315.

Mulder P, Morrison MC, Wielinga PY, van Duyvenvoorde W, Kooistra T, Kleemann R. Surgical removal of inflamed epididymal white adipose tissue attenuates the development of non-alcoholic steatohepatitis in obesity. **Int J Obes (Lond)** **2015** Oct 26. doi: 10.1038/ijo.2015.226. [Epub ahead of print]

Morrison MC, Mulder P, Stavro PM, Suárez M, Arola-Arnal A, van Duyvenvoorde W, Kooistra T, Wielinga PY, Kleemann R. Replacement of dietary saturated fat by PUFA-rich pumpkin seed oil attenuates non-alcoholic fatty liver disease and atherosclerosis development, with additional health effects of virgin over refined oil. **PLoS One** **2015**;10:e0139196. doi: 10.1371/journal.pone.0139196. *

Morrison M, Liang W, Mulder P, Toet K, Heeringa P, Wielinga P, Kooistra T, Kleemann R. Mirtoselect, an anthocyanin-rich bilberry extract, attenuates non-alcoholic steatohepatitis and associated fibrosis in ApoE*3Leiden mice. **J Hepatol** **2015**; 62: 1180-1186. doi: 10.1016/j.jhep.2014.12.011.

Morrison MC, Kleemann R. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic co-morbidities: a comprehensive review of human and rodent studies. **Front Immunol** **2015**; 15: 308. doi: 10.3389/fimmu.2015.00308.

van der Heijden RA, Sheedfar F, Morrison MC, Hommelberg PP, Kor D, Kloosterhuis NJ, Gruben N, Youssef SA, de Bruin A, Hofker MH, Kleemann R, Koonen DP, Heeringa P. High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice. **Aging (Albany NY)** **2015**;7:256-68.

Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, Havekes LM, Kleemann R, van den Hoek AM. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. **PLoS ONE** **2014**; 9: e115922. doi: 10.1371/journal.pone.0115922.

Liang W, Lindeman JH, Menke AL, Koonen DP, Morrison M, Havekes LM, van den Hoek AM, Kleemann R. Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1b-induced chronic inflammation. **Lab Invest** **2014**; 94: 491-502. doi:10.1038/labinvest.2014.11.

Van den Hoek AM, van der Hoorn JWA, Maas AC, van den Hoogen RM, van Nieuwkoop A, Droog S, Offerman EH, Pieterman EJ, Havekes LM, Princen HMG. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the Metabolic Syndrome. **Diabet Obes Metab** **2014**; 16: 537-544.

Wang Y, Parlevliet ET, Geerling JJ, van der Tuin SJ, Zhang H, Bieghs V, Jawad AH, Shiri-Sverdlov R, Bot I, de Jager SC, Havekes LM, Romijn JA, Willems van Dijk K, Rensen PC. Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. **Br J Pharmacol** **2014**; 171: 723-34. doi: 10.1111/bph.12490

Nachabé R, van der Hoorn JW, van de Molengraaf R, Lamerichs R, Pikkemaat J, Sio CF, Hendriks BH, Sterenborg HJ. Validation of interventional fiber optic spectroscopy with MR spectroscopy, MAS-NMR spectroscopy, high-performance thin-layer chromatography, and histopathology for accurate hepatic fat quantification. **Invest Radiol.** **2012** Apr;47(4):209-16. *



Van Ginneken V, Verhey E, Poelmann R, Ramakers R, van Dijk KW, Ham L, Voshol P, Havekes L, Van Eck M, van der Greef J. Metabolomics (liver and blood profiling) in a mouse model in response to fasting: a study of hepatic steatosis. **Biochim Biophys Acta** **2007**; 1771: 1263-1270.

den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. **Arterioscler Thromb Vasc Biol** **2004**; 24: 644-649.

Muscle health and frailty

de Jong JCBC, Jameson TSO, Andrews RC, Dunlop MV, Abdelrahman DR, Murton AJ, Caspers MPM, Worms N, van Nieuwkoop A, Keijzer N, Cheng Q, Guigas B, van Duijn E, Vaes WHJ, Nieuwenhuizen AG, Keijzer J, Wall BT, Verschuren L, Stephens FB, van den Hoek AM, Dirks ML. Anabolic effects of salbutamol are lost upon immobilization. **J Cachexia Sarcopenia Muscle** **2025**; 16: e70114. doi.org/10.1002/jcsm.70114.

de Jong JCBC, Caspers MPM, Dullos R, Snabel J, van der Hoek MD, van der Leij FR, Kleemann R, Keijzer J, Nieuwenhuizen AG, van den Hoek AM, Verschuren L. Blood-based biomarkers for early frailty are sex-specific: validation of a combined in silico prediction and data-driven approach. **Geroscience** **2025**; 47:3741-3758. doi: 10.1007/s11357-024-01449-w.

van de Meene MRC, van den Hoek AM, Hanemaaijer R, Verschuren L, de Jong JCBC. In vitro muscle contraction: A technical review on electrical pulse stimulation in C2C12 cells. **Exp Physiol** **2025**; 1-16. DOI: 10.1113/EP092677.

de Jong JCBC, Caspers MPM, Worms N, Keijzer N, Kleemann R, Menke AL, Nieuwenhuizen AG, Keijzer J, Verschuren L, van den Hoek AM. Translatability of mouse muscle-aging for humans: the role of sex. **Geroscience** **2024**; 46: 3341-3360. doi: 10.1007/s11357-024-01082-7.

de Jong JCBC, Caspers MPM, Keijzer N, Worms N, Attema J, de Ruiter C, Lek S, Nieuwenhuizen AG, Keijzer J, Menke AL, Kleemann R, Verschuren L, van den Hoek AM. Caloric restriction combined with immobilization as translational model for sarcopenia expressing key-pathways of human pathology. **Aging Dis** **2023**; 14: 937-957. doi: 10.14336/AD.2022.1201.

van den Hoek AM, de Jong JCBC, Worms N, van Nieuwkoop A, Voskuilen M, Menke AL, Lek S, Caspers MPM, Verschuren L, Kleemann R. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. **Metabolism** **2021**; 124:154873. doi: 10.1016/j.metabol.2021.154873.

van der Hoek MD, Nieuwenhuizen AG, Kuda O, Bos P, Paluchová V, Verschuren L, van den Hoek AM, Kleemann R, Veeger NJGM, van der Leij FR, Keijzer J. Intramuscular short-chain acylcarnitines in elderly people are decreased in (pre-)frail females, but not in males. **FASEB J** **2020**; 34:11658-11671. Doi: 10.1096/fj.202000493R.

van den Hoek AM, Zondag GCM, Verschuren L, de Ruiter C, Attema J, de Wit EC, Schwerk AMK, Guigas B, Lek S, Rietman A, Strijker R, Kleemann R. A novel nutritional supplement prevents muscle loss and accelerates muscle mass recovery in caloric-restricted mice. **Metabolism** **2019**; 97:57-67. doi: 10.1016/j.metabol.2019.05.012. *

Obesity, insulin resistance, type 2 diabetes and fatty acid metabolism

van Tuijl J, Vreeken D, Broeders W, Cossins B, van Emst L, Seidel F, Stienstra R, Li Y, Joosten LAB, Netea MG, Hazebroek EJ, Kleemann R, Kiliaan AJ, Bekkering S, Rixen NP. The long-term effect of metabolic bariatric surgery on innate immune cell phenotype and function. **Int J Obes** **2025**; 49: 2473–2483. doi.org/10.1038/s41366-025-01886-3.

Gart E, Snabel, de Jong JCBC, Verschuren L, van den Hoek AM, Morrison MC, Kleemann R. Biomarkers of metabolism and inflammation in individuals with obesity and normal weight-A comparative analysis exploring sex differences. **Int J Mol Sci** **2025**; 26, 7576. doi.org/10.3390/ijms26157576.

Oosterman JE, Smid DJ, Kamstra RJM, de Hoogh IM, Huizing AHJ, Caspers MPM, van den Broek TJ, Kleemann R, van Empelen P, ter Beek J, Pasman WJ, Woperies S. Personalisation of the Dutch combined lifestyle intervention SLIMMER improves participant retention and weight loss in people at risk for cardiometabolic disease. **Sci Rep** **2025**; 15:44347. doi.org/10.1038/s41598-025-27899-6.

Custers E, van der Burgh YGR, Vreeken D, Schuren F, van den Broek TJ, Verschuren L, de Blaauw I, Bouwens M,



Kleemann R, Kiliaan AJ, Hazebroek EJ. Gastrointestinal complaints after Roux-en-Y gastric bypass surgery. Impact of microbiota and its metabolites. **Heliyon** **2024**; 10: e39899. doi: 10.1016/j.heliyon.2024.e39899.

Custers E, Vreeken D, Schuren F, van den Broek TJ, van Dongen L, Geenen B, de Blaauw I, Wiesmann M, Hazebroek EJ, Kleemann R, Kiliaan AJ. Impact of microbiota and metabolites on intestinal integrity and inflammation in severe obesity. **Pharmaceuticals** **2024**; 10: 918. doi: 10.3390/ph17070918.

Morrison MC, Egelandssdal B, Harvei S, Rocha SDC, Pieterman EJ, Kleemann R, Carlsen H. Differential effects of plant and animal fats on obesity-induced dyslipidemia and atherosclerosis in Ldlr^{-/-}.Leiden mice. **FASEB J** **2023**; 37:e23096. doi.org/10.1096/fj.202300585R.

Olga L, Bobeldijk-Pastorova I, Bas RC, Ong KK, Kleemann R, Koulman A. Lipid profiling analyses from mouse models and human infants. **STAR Protocols** **2022**; 3: 101679. doi.org/10.1016/j.xpro.2022.101679.

Komninos D, Ramos L, van der Heijden GW, Morrison MC, Kleemann R, van Herwaarden AE, Kiliaan AJ, Arnoldussen IAC. **Sci Rep** **2022**; 12: 430. doi.org/10.1038/s41598-021-04069-y.

Davies R, van Diepen JA, Brink LR, Bijlsma S, McVey Neufeld KA, Cryan JF, O'Mahony SM, Bobeldijk I, Gross G. Lipidome analysis in brain and peripheral plasma following milk fat globule membrane supplementation in rodents. **Mol Nutr Food Res** **2022**; 2200177. doi: 10.1002/mnfr.202200177

Olga L, van Diepen JA, Bobeldijk-Pastorova I, Gross G, Prentice PM, Snowden SG, Furse S, Kooistra T, Hughes IA, Schoemaker MH, van Tol EAF, van Duyvenvoorde W, Wielinga PY, Ong KK, Dunger DB, Kleemann R, Koulman A. Lipid ratios representing SCD1, FADS1, and FADS2 activities as candidate biomarkers of early growth and adiposity. **EBioMedicine** **2021**; 63: 103198. doi.org/10.1016/j.ebiom.2020.103198.

van den Hoek AM, Pieterman EJ, van der Hoorn JW, Iruarrizaga-Lejarreta M, Alonso C, Verschuren L, Skjæret T, Princen HMG, Fraser DA. Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity and fibrosis in mice. **Hepato Comm** **2020**; 4: 193-207. doi:10.1002/hep4.1453 *

van den Brink W, van Bilsen J, Salic K, Hoevenaars FPM, Verschuren L, Kleemann R, Bouwman J, Ronnett GV, van Ommen B, Wopereis S. Current and future nutritional strategies to modulate inflammatory dynamics in metabolic disorders. **Front Nutr** **2019**; 6: 129. doi: 10.3389/fnut.2019.00129.

Pouwer MG, Heinonen SE, Behrendt M, Andréasson AC, van Koppen A, Menke AL, Pieterman EJ, van den Hoek AM, Jukema JWJ, Leighton B, Jönsson- Rylander AC, Princen HMG. The APOE*3-Leiden.heterozygous glucokinase knockout mouse as novel translational disease model for type 2 diabetes, dyslipidemia and diabetic atherosclerosis. **J Diab Res** **2019**; Article ID 9727952. doi.org/10.1155/2019/9727952. *

Luque-Sierra A, Alvarez-Amor L, Kleemann R, Martín F, Varela LM. Extra-Virgin Olive Oil With Natural Phenolic Content Exerts an Anti-Inflammatory Effect in Adipose Tissue and Attenuates the Severity of Atherosclerotic Lesions in Ldlr^{-/-}.Leiden Mice. **Mol Nutr Food Res** **2018** Jul;62(13):e1800295. doi: 10.1002/mnfr.201800295.

Pelgrim CE, Franx BAA, Snabel J, Kleemann R, Arnoldussen IAC, Kiliaan AJ. Butyrate Reduces HFD-Induced Adipocyte Hypertrophy and Metabolic Risk Factors in Obese LDLr^{-/-}.Leiden Mice. **Nutrients** **2017**; 9: pii: E714. doi: 10.3390/nu9070714.

Morrison MC, Yakala GK, Liang W, Wielinga PY, Salic K, van Koppen A, Tomar T, Kleemann R, Heeringa P, Kooistra T. Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21? **Sci Rep** **2017**; 6: 7: 2915. doi: 10.1038/s41598-017-02444-2

Zwamborn RA, Slieker RC, Mulder PC, Zoetemelk I, Verschuren L, Suchiman HE, Toet KH, Droog S, Slagboom PE, Kooistra T, Kleemann R, Heijmans BT. Prolonged high-fat diet induces gradual and fat depot-specific DNA methylation changes in adult mice. **Sci Rep** **2017**; 3: 7: 43261. doi: 10.1038/srep43261.

Arnoldussen IAC, Wiesmann M, Pelgrim CE, Wielemaker EM, van Duyvenvoorde W, Amaral-Santos PL, Verschuren L, Keijser BJF, Heerschap A, Kleemann R, Wielinga PY, Kiliaan AJ. Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice. **Int J Obes (Lond)**. **2017**; 41: 935-944. doi: 10.1038/ijo.2017.52.

van der Heijden RA, Morrison MC, Sheedfar F, Mulder P, Schreurs M, Hommelberg PP, Hofker MH, Schalkwijk C, Kleemann R, Tietge UJ, Koonen DP, Heeringa P. Effects of Anthocyanin and Flavanol Compounds on Lipid Metabolism and Adipose Tissue Associated Systemic Inflammation in Diet-Induced Obesity. **Mediators Inflamm** **2016**; 2016: 2042107. doi: 10.1155/2016/2042107.

Arnoldussen IA, Zerbi V, Wiesmann M, Noordman RH, Bolijn S, Mutsaers MP, Dederen PJ, Kleemann R, Kooistra T, van Tol EA, Gross G, Schoemaker MH, Heerschap A, Wielinga PY, Kiliaan AJ. Early intake of long-chain polyunsaturated fatty acids preserves brain structure and function in diet-induced obesity. **J Nutr Biochem.** **2016**; 30:177-188. doi: 10.1016/j.jnutbio.2015.12.011.

van der Heijden RA, Bijzet J, Meijers WC, Yakala GK, Kleemann R, Nguyen TQ, de Boer RA, Schalkwijk CG, Hazenberg BP, Tietge UJ, Heeringa P. Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. **Sci Rep.** **2015**;5:16474. doi: 10.1038/srep16474.

Berbée JF, Boon MR, Khedoe PP, Bartelt A, Schlein C, Worthmann A, Kooijman S, Hoeke G, Mol IM, John C, Jung C, Vazirpanah N, Brouwers LP, Gordts PL, Esko JD, Hiemstra PS, Havekes LM, Scheja L, Heeren J, Rensen PC. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. **Nat Commun** **2015**; 6: 6356. doi: 10.1038/ncomms7356.

van Dam AD, Nahon KJ, Kooijman S, van den Berg SM, Kanhai AA, Kikuchi T, Heemskerk MM, van Harmelen V, Lombès M, van den Hoek AM, de Winther MP, Lutgens E, Guigas B, Rensen PC, Boon MR. Salsalate activates brown adipose tissue in mice. **Diabetes** **2015**; 64: 1544-1554. doi: 10.2337/db14-1125.

van der Heijden RA, Sheedfar F, Morrison MC, Hommelberg PH, Kor D, Kloosterhuis NJ, Gruben N, Youssef SA, de Bruin A, Hofker MH, Kleemann R, Koonen DY, Heeringa P. High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice. **Aging (Albany NY)** **2015**; 7:256-268.

Boon MR, Kooijman S, van Dam AD, Pelgrom LR, Berbée JF, Visseren CA, van Aggele RC, van den Hoek AM, Sips HC, Lombès M, Havekes LM, Tamsma JT, Guigas B, Meijer OC, Jukema JW, Rensen PC. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. **FASEB J** **2014**; 28: 5361-5375.

Geerling JJ, Boon MR, van der Zon GC, van den Berg SAA, van den Hoek AM, Lombès M, Princen HMG, Havekes LM, Rensen PCN, Guigas B. Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice. **Diabetes** **2014**; 63: 880-891.

Kooijman S, Boon MR, Parlevliet ET, Geerling JJ, van de Pol V, Romijn JA, Havekes LM, Meurs I, Rensen PC. Inhibition of the central melanocortin system decreases brown adipose tissue activity. **J Lipid Res** **2014**;55: 2022-2032.

Van den Hoek AM, van der Hoorn JWA, Maas AC, van den Hoogen RM, van Nieuwkoop A, Droog S, Offerman EH, Pieterman EJ, Havekes LM, Princen HMG. APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the Metabolic Syndrome. **Diabet Obes Metab** **2014**; 16: 537-544. doi:10.1212/WNL.0000000000201538.

Sugimoto-Kawabata K, Shimada H, Sakai K, Suzuki K, Kelder T, Pieterman EJ, Cohen LH, Havekes LM, Princen HM, van den Hoek AM. Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion. **J Lipid Res** **2013**; 54:1255-1264. *

Liang W, Tonini G, Mulder P, Kelder T, van Erk M, van den Hoek AM, Mariman R, Wielinga PY, Baccini M, Kooistra T, Biggeri A, Kleemann R. Coordinated and interactive expression of genes of lipid metabolism and inflammation in adipose tissue and liver during metabolic overload. **PLOS One** **2013**; 8: e75290.

Coomans CP, van den Berg SA, Lucassen EA, Houben T, Pronk AC, van der Spek RD, Kalsbeek A, Biermasz NR, Willems van Dijk K, Romijn JA, Meijer JH. The suprachiasmatic nucleus controls circadian energy metabolism and hepatic insulin sensitivity. **Diabetes** **2013**; 62: 1102-1108.

van den Berg SA, Heemskerk MM, Geerling JJ, van Klinken JB, Schaap FG, Bijland S, Berbée JF, van Harmelen VJ, Pronk AC, Schreurs M, Havekes LM, Rensen PC, van Dijk KW. Apolipoprotein A5 deficiency aggravates high-fat diet-induced obesity due to impaired central regulation of food intake. **FASEB J** **2013**; 27: 3354-3362.

Vroegrijk IO, van Klinken JB, van Diepen JA, van den Berg SA, Febbraio M, Steinbusch LK, Glatz JF, Havekes LM, Voshol PJ, Rensen PC, van Dijk KW, van Harmelen V. CD36 is important for adipocyte recruitment and affects lipolysis. **Obesity (Silver Spring)** **2013**; Mar 20. doi: 10.1002/oby.20354. [Epub ahead of print]

Geerling JJ, Wang Y, Havekes LM, Romijn JA, Rensen PC. Acute central neuropeptide Y administration increases food intake but does not affect hepatic very low-density lipoprotein (VLDL) production in mice. **PLOS One** **2013**; 8:



e55217. doi: 10.1371/journal.pone.0055217.

Radonjic M, Wielinga PY, Wopereis S, Kelder T, Goelela VS, Verschuren L, Toet K, van Duyvenvoorde W, van der Werf van der Vat B, Stroeve JH, Cnubben N, Kooistra T, van Ommen B, Kleemann R. Differential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- mice. **PLOS One** 2013; 8:e56122. doi: 10.1371/journal.pone.0056122.

Coomans CP, van den Berg SA, Houben T, van Klinken JB, van den Berg R, Pronk AC, Havekes LM, Romijn JA, Willems van Dijk K, Biermasz NR, Meijer JH. Detrimental effects of constant light exposure and high-fat diet on circadian energy metabolism and insulin sensitivity. **FASEB J** 2013; 27: 1721-1732. doi: 10.1096/fj.12-210898.

Oksaharju A, Kooistra T, Kleemann R, v Duivenvoorde W, Miettinen M, Lappalainen J, Korpela R, Lindstedt KA, Kovanen PT, Kekkonen RA. Effects of probiotic *Lactobacillus rhamnosus* GG and *Propionibacterium freudenreichii* ssp. *shermanii* JS supplementation on intestinal and systemic markers of inflammation in ApoE*3 Leiden mice consuming a high-fat diet. **Br J Nutr** 2013; 110: 77-85. *

Yakala GK, van der Heijden R, Molema I, Schipper M, Wielinga PY, Kleemann R, Kooistra T, Heeringa P. Beneficial effects of an alternating high- fat dietary regimen on systemic insulin resistance, liver and renal inflammation and renal function. **PLoS One** 2012; 7: e45866.

Gierman LM, van der Ham F, Koudijs A, Wielinga PY, Kleemann R, Kooistra T, Stoop R, Kloppenburg M, van Osch GJ, Stojanovic-Susulic V, Huizinga TW, Zuurmond AM. Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice. **Arthritis Rheum** 2012; 64:1172-1181. doi: 10.1002/art.33443.

Vroegrijk IO, van Diepen JA, van den Berg SA, Romijn JA, Havekes LM, van Dijk KW, Darland G, Konda V, Tripp ML, Bland JS, Voshol PJ. META060 protects against diet-induced obesity and insulin resistance in a high-fat-diet fed mouse. **Nutrition** 2013; 29: 276-283.

Auvinen HE, Romijn JA, Biermasz NR, Pijl H, Havekes LM, Smit JW, Rensen PC, Pereira AM. The effects of high fat diet on the basal activity of the hypothalamus-pituitary-adrenal axis in mice. **J Endocrinol** 2012; 214: 191-197.

Van Klinken JB, van den Berg SA, Havekes LM, Willems Van Dijk K. Estimation of activity related energy expenditure and resting metabolic rate in freely moving mice from indirect calorimetry data. **PLOS One** 2012; 7:e36162.

Wopereis S, Radonjic M, Rubingh C, van Erk M, Smilde A, van Duyvenvoorde W, Cnubben N, Kooistra T, van Ommen B, Kleemann R. Identification of prognostic and diagnostic biomarkers of glucose intolerance in ApoE3Leiden mice. **Physiol Genomics** 2012; 44: 293-304.

Coomans CP, Biermasz NR, Geerling JJ, Guigas B, Rensen PC, Havekes LM, Romijn JA. Stimulatory effect of insulin on glucose uptake by muscle involves the central nervous system in insulin-sensitive mice. **Diabetes** 2011 ; 60: 3132-3140.

Kelder T, Eijssen L, Kleemann R, van Erk M, Kooistra T, Evelo C. Exploring pathway interactions in insulin resistant mouse liver. **BMC Syst Biol** 2011; 5:127. doi: 10.1186/1752-0509-5-127.

Scully MS, Ort TA, James IE, Bugelski PJ, Makropoulos DA, Deutsch HA, Pieterman EJ, van den Hoek AM, Havekes LM, Dubell WH, Wertheimer JD, Picha KM. A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. **Exp Diabetes Res** 2011; 2011: 910159.

Coomans CP, Geerling JJ, Guigas B, van den Hoek AM, Parlevliet ET, Ouwens DM, Pijl H, Voshol PJ, Rensen PC, Havekes LM, Romijn JA. Circulating insulin stimulates fatty acid retention in white adipose tissue via KATP channel activation in the central nervous system only in insulin-sensitive mice. **J Lipid Res** 2011; 52: 1712-1722.

De Vogel-van den Bosch J, van den Berg SA, Bijland S, Voshol PJ, Havekes LM, Romijn HA, Hoeks J, van Beurden D, Hesselink MK, Schrauwen P, van Dijk KW. High-fat diets rich in medium- versus long-chain fatty acids induce distinct patterns of tissue specific insulin resistance. **J Nutr Biochem** 2011; 22: 366-371.

Vroegrijk IO, van Diepen JA, van den Berg S, Westbroek I, Keizer H, Gambelli L, Hontecillas R, Bassaganya-Riera J, Zondag GC, Romijn JA, Havekes LM, Voshol PJ. Pomegranate seed oil, a rich source of punicic acid, prevents diet-induced obesity and insulin resistance in mice. **Food Chem Toxicol** 2011; 49: 1426-1430.

Kleemann R, van Erk M, Verschuren L, van den Hoek AM, Koek M, Wielinga PY, Jie A, Pellis L, Bobeldijk-Pastorova I, Kelder T, Toet K, Wopereis S, Cnubben N, Evelo C, van Ommen B, Kooistra T. Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. **PLOS One** 2010; 5: 1-16

Caesar R, Manieri M, Kelder T, Boekschoten M, Evelo C, Muller M, Kooistra T, Cinti S, Kleemann R, Drevon CA. A combined transcriptomics and lipidomics analysis of subcutaneous, epididymal and mesenteric adipose tissue reveals marked functional differences. **PLOS One** 2010; 5: 1-14. e11525

van den Berg SA, Nabben M, Bijland S, Voshol PJ, van Klinken JB, Havekes LM, Romijn JA, Hoeks J, Hesselink MK, Schrauwen P, van Dijk KW. High levels of whole-body energy expenditure are associated with a lower coupling of skeletal muscle mitochondria in C57Bl/6 mice. **Metabolism** 2010; 59: 1612-1618.

de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H, Guigas B. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. **Biochem Pharmacol** 2010; 79: 1827-1836.

van den Berg SA, Guigas B, Bijland S, Ouwens M, Voshol PJ, Frants RR, Havekes LM, Romijn JA, van Dijk KW. High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity. **Nutr Metab (Lond)** 2010; 7: 24.

Voshol PJ, Rensen PC, van Dijk KW, Romijn JA, Havekes LM. Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. **Biochim Biophys Acta** 2009 1791: 479-485. **Review.**

Klieverik LP, Coomans CP, Endert E, Sauerwein HP, Havekes LM, Voshol PJ, Rensen PC, Romijn JA, Kalsbeek A, Fliers E. Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. **Endocrinology** 2009; 150: 5639-5648.

Carlsen H, Haugen F, Zadelaar S, Kleemann R, Kooistra T, Drevon CA, Blomhoff R. Diet-induced obesity increases NF-kappaB signaling in reporter mice. **Genes Nutr** 2009; 4: 215-222.

Verschuren L, Kooistra T, Bernhagen J, Voshol PJ, Ouwens M, van Erk M, de Vries-van der Weij J, Leng L, van Bockel JH, Willems van Dijk K, Fingerle-Rowson G, Bucala R, Kleemann R. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. **Circ Res** 2009; 105: 99-107.

Parlevliet ET, Schröder-van der Elst JP, Corssmit EP, Picha K, O'Neil K, Stojanovic-Susulic V, Ort T, Havekes LM, Romijn JA, Pijl H. CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice. **J Pharmacol Exp Ther** 2009; 328: 240-248. *

Van den Hoek AM, van Heijningen C, Schröder-van der Elst JP, Ouwens DM, Havekes LM, Romijn JA, Kalsbeek A, Pijl H. Intracerebroventricular administration of neuropeptide Y induces hepatic insulin resistance via sympathetic innervation. **Diabetes** 2008; 57: 2304-2310.

Van den Hoek AM, Teusink B, Voshol PJ, Havekes LM, Romijn JA, Pijl H. Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. **J Neuroendocrinol** 2008; 20: 120-127.

Madsen L, Pedersen LM, Liaset B, Ma T, Petersen RK, van den Berg S, Pan J, Müller-Decker K, Dülser ED, Kleemann R, Kooistra T, Døskeland SO, Kristiansen K. cAMP-dependent signaling regulates the adipogenic effect of n-6 polyunsaturated fatty acids. **J Biol Chem** 2008; 283: 7196-7205.

Parlevliet ET, Heijboer AC, Schröder-van der Elst JP, Havekes LM, Romijn JA, Pijl H, Corssmit EP. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. **Am J Physiol Endocrinol Metab** 2008; 294: E142-147.

Van den Hoek AM, Teusink B, Voshol PJ, Havekes LM, Romijn JA, Pijl H. Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. **J Neuroendocrinol** 2008; 20: 120-127.

Van den Hoek AM, Heijboer AC, Voshol PJ, Havekes LM, Romijn JA, Corssmit EP, Pijl H. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. **Am J Physiol Endocrinol Metab** 2007; 292: E238-245.

Korshennikova E, Voshol PJ, Baan B, van der Zon GC, Havekes LM, Romijn JA, Maassen JA, Ouwens DM. Dynamics of insulin signalling in liver during hyperinsulinemic euglycaemic clamp conditions in vivo and the effects of high-fat feeding in male mice. **Arch Physiol Biochem** 2007; 113: 173-185.

Heijboer AC, Pijl H, Van den Hoek AM, Havekes LM, Romijn JA, Corssmit EP. Gut-brain axis: regulation of glucose metabolism. **J Neuroendocrinol** 2006; 18: 883-894. **Review**



Korshennikova E, van der Zon GC, Voshol PJ, Janssen GM, Havekes LM, Grefhorst A, Kuipers F, Reijngoud DJ, Romijn JA, Ouwers DM, Maassen JA. Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice. **Diabetologia** 2006; 49: 3049-57.

Den Boer MA, Voshol PJ, Kuipers F, Romijn JA, Havekes LM. Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production. **Am J Physiol Endocrinol Metab** 2006; 291: E1360-4.

Den Boer MA, Voshol PJ, Schröder-van der Elst JP, Korshennikova E, Ouwers DM, Kuipers F, Havekes LM, Romijn JA. Endogenous interleukin-10 protects against hepatic steatosis but does not improve insulin sensitivity during high-fat feeding in mice. **Endocrinology** 2006; 147: 4553-4558.

Heijboer AC, van den Hoek AM, Parlevliet ET, Havekes LM, Romijn JA, Pijl H, Corssmit EP. Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. **Diabetologia** 2006; 49: 732-738.

Zadelaar ASM, Boesten LSM, Jukema JW, van Vlijmen BJM, Kooistra T, Emeis JJ, Lundholm E, Camejo G, Havekes LM. Dual PPAR α /y agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic APOE*3-Leiden mice. **Arterioscler Thromb Vasc Biol** 2006; 26: 2560-2566. *

Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. **Diabetes** 2005; 54: 664-671.

de Roos B, Duivenvoorden I, Rucklidge G, Reid M, Ross K, Lamers RJ, Voshol PJ, Havekes LM, Teusink B. Response of apolipoprotein E*3-Leiden transgenic mice to dietary fatty acids: combining liver proteomics with physiological data. **FASEB J** 2005; 19: 813-815

Heijboer AC, Voshol PJ, Donga E, van Eden CG, Havekes LM, Romijn JA, Pijl H, Corssmit EP. High fat diet induced hepatic insulin resistance is not related to changes in hypothalamic mRNA expression of NPY, AgRP, POMC and CART in mice. **Peptides** 2005; 26: 2554-2558.

Heijboer AC, van den Hoek AM, Pijl H, Voshol PJ, Havekes LM, Romijn JA, Corssmit EP. Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. **Diabetologia** 2005; 48: 1621-1626.

Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reijngoud DJ, Kuipers F. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. **Am J Physiol Endocrinol Metab** 2005; 289: E829-838.

Grefhorst A, Hoekstra J, Derks TG, Ouwers DM, Baller JF, Havinga R, Havekes LM, Romijn JA, Kuipers F. Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. **Am J Physiol Gastrointest Liver Physiol** 2005; 289: G592-598.

Duivenvoorden I, Teusink B, Rensen PC, Kuipers F, Romijn JA, Havekes LM, Voshol PJ. Acute inhibition of hepatic beta-oxidation in APOE*3Leiden mice does not affect hepatic VLDL secretion or insulin sensitivity. **J Lipid Res** 2005; 46: 988-993.

Heijboer AC, Donga E, Voshol PJ, Dang ZC, Havekes LM, Romijn JA, Corssmit EP. Sixteen hours of fasting differentially affects hepatic and muscle insulin sensitivity in mice. **J Lipid Res** 2005; 46: 582-588.

VandenHoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM, and Pijl H. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. **Diabetes** 2004; 53: 2529-2534.

VandenHoek AM, Heijboer AC, Corssmit EPM, Voshol PJ, Romijn JA, Havekes LM, and Pijl H. PYY3-36 Reinforces insulin action on glucose disposal in mice fed a high-fat diet. **Diabetes** 2004; 53: 1949-1952.

Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, März W, Tafuri S, Wahli W, Müller M, Kersten S. PPAR α governs glycerol metabolism. **J Clin Invest** 2004; 114: 94-103.

Goudriaan JR, Espirito Santo SMS, Voshol PJ, Teusink B, WillemsvanDijk K, vanVlijmen BJM, Romijn JA, Havekes LM, and Rensen PCN. The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. **J Lipid Res** 2004; 45: 1475-1481.

Muurling M, van den Hoek AM, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Overexpression of APOC1 in ob/ob mice leads to hepatic steatosis and severe hepatic insulin resistance. **J Lipid Res** 2004; 45: 9-16.

Fliers E, Kreier F, Voshol PJ, Havekes LM, Sauerwein HP, Kalsbeek A, Buijs RM, Romijn JA. White adipose tissue: getting nervous. **J Neuroendocrinol** 2003; 15: 1005-10. **Review**

Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. A fish oil diet does not reverse insulin resistance despite decreased adipose tissue TNF-alpha protein concentration in ApoE-3*Leiden mice. **J Nutr** 2003; 133: 3350-3356.

Goudriaan J, Dahlmans VEH, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. **J Lipid Res** 2003; 44: 2270-2277.

Muurling M, Mensink RP, Pijl H, Romijn JA, Havekes LM, Voshol PJ. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice. **Metabolism** 2003; 52: 1078-1083.

Voshol PJ, Haemmerle G, Ouwens DM, Zimmermann R, Zechner R, Teusink B, Maassen JA, Havekes LM, Romijn JA. Increased hepatic insulin sensitivity together with decreased hepatic triglyceride stores in hormone-sensitive lipase-deficient mice. **Endocrinology** 2003; 144: 3456-3462.

Teusink B, Voshol PJ, Dahlmans VEH, Rensen PCN, Pijl H, Romijn JA, Havekes LM. Contribution of fatty acids released from plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. **Diabetes** 2003; 52: 614-620.

Kreier F, Fliers E, Voshol PJ, van Eden CG, Havekes LM, Kalsbeek A, van Heijningen CL, Sluiter AA, Mettenleiter TC, Romijn JA, Sauerwein HP, Buijs RM. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat-functional implications. **J Clin Invest** 2002; 110: 1243-1250.

Grefhorst A, Elzinga BM, Voshol PJ, Plosch T, Kok T, Bloks VW, Van Der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ, Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor (LXR) leads to production of large, triglyceride-rich VLDL particles. **J Biol Chem** 2002; 277: 34182-34190.

Goudriaan J, Dahlmans VEH, Febbraio M, Teusink B, Romijn JA, Havekes LM, Voshol PJ. Intestinal lipid absorption is not affected in CD36 deficient mice. **Mol Cell Biochem** 2002; 239: 199-202.

Muurling M, Jong MC, Mensink RP, Hornstra G, Dahlmans VE, Pijl H, Voshol PJ, Havekes LM. A low-fat diet has a higher potential than energy restriction to improve high-fat diet-induced insulin resistance in mice. **Metabolism** 2002; 51: 695-701.

Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. **J Hepatol** 2001; 35: 816-822. **Review**

Jong MC, Voshol PJ, Muurling M, Dahlmans VEH, Romijn JA, Pijl H, Havekes LM. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. **Diabetes** 2001; 50: 2779-2785.

Goudriaan J, Tacke P, Dahlmans VEH, Gijbels M, Willems van Dijk K, Havekes LM, Jong MC. Protection from obesity in mice lacking the very low density lipoprotein receptor. **Arterioscler Thromb Vasc Biol** 2001; 21: 1488-1493.

Voshol PJ, Jong MC, Dahlmans VEH, Kratky D, Levak-Frank S, Zechner R, Romijn JA, Havekes LM. In muscle-specific LPL overexpression mice muscle triglyceride content is increased, without inhibition of insulin-stimulated whole body and muscle specific glucose uptake. **Diabetes** 2001; 50: 2585-2590.

Koopmans SJ, Jong MC, Que I, Dahlmans VEH, Pijl H, Radder JK, Frölich M, Havekes LM. Hyperlipidemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing apolipoprotein C1. **Diabetologia** 2001; 44: 437-443.

Chronic inflammation and inflammatory diseases

van Gemert Y, Blom AB, Di Ceglie I, Walgreen B, Helsen M, Sloetjes A, Vogl T, Roth J, Kruisbergen NNL, Pieterman EJ, Princen HMG, van der Kraan PM, van Lent PLEM, van den Bosch MHJ. Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease

in dyslipidemic female E3L.CETP mice. **Osteoarthritis Cartilage** 2023; 31: 934-943. doi.org/10.1016/j.joca.2023.01.577
van Gemert Y, Kruisbergen NNL, Blom AB, van den Bosch MHJ, van der Kraan PM, Pieterman EJ, Princen HMG, van Lent PLEM. IL-1 β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model. **Osteoarthritis Cartilage** 2023; 31: 340-350. doi.org/10.1016/j.joca.2022.09.014.

Gart E, Salic K, Morrison MC, Caspers M, van Duyvenvoorde W, Heijnk M, Giera M, Bobeldijk-Pastorova I, Keijer J, Storsve AB, Hals PA, Kleemann R. Krill Oil Treatment Increases Distinct PUFAs and Oxylipins in Adipose Tissue and Liver and Attenuates Obesity-Associated Inflammation via Direct and Indirect Mechanisms. **Nutrients** 2021;13(8):2836. doi: 10.3390/nu13082836.

van Bilsen JHM, van den Brink W, van den Hoek AM, Dulos R, Caspers MPM, Kleemann R, Wopereis S, Verschuren L. Mechanism-based biomarker prediction for low-grade inflammation in liver and adipose tissue. **Front Physiol** 2021;12: 703370. doi: 10.3389/fphys.2021.703370

van Gemert Y, Kozijn AE, Pouwer MG, Kruisbergen NNL, van den Bosch MHJ, Blom AB, Pieterman EJ, Weinans H, Stoop R, Princen HMG, van Lent PLEM. Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice. **Osteoarthritis Cartilage** 2021; 29: 1314-1323. doi.org/10.1016/j.joca.2021.02.570.

Pieterman E, Princen HMG, Jarke A, Nilsson R, Cavallin A, Bergenholm L, Henricsson M, Gopaul VS, Agrawal R, Nissen S, Hurt-Camejo E. Chronic oral administration of mineral oil compared with corn oil: Effects on gut permeability and plasma inflammatory and lipid biomarkers. **Front Pharmacol** 2021; 12: 681455. doi: 10.3389/fphar.2021.681455.

Warmink K, Kozijn AE, Bobeldijk I, Stoop R, Weinans H, Korthagen NM. High-fat feeding primes the mouse knee joint to develop osteoarthritis and pathologic infrapatellar fat pad changes after surgically induced injury. **Osteoarthritis Cartilage** 2020; 28: 593-602. doi.org/10.1016/j.joca.2020.03.008.

Kozijn AE, Gierman LM, van der Ham F, Mulder P, Morrison MC, Kühnast S, Stavro MP, van Koppen A, Pieterman EJ, van den Hoek AM, Kleemann R, Princen HMG, Mastbergen SC, Lafeber FPJG, Zuurmond AM, Bobeldijk I, Weinans H, Stoop R. Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought. **Osteoarthritis Cartilage** 2018; 26: 95-107. doi.org/10.1016/j.joca.2017.10.010.

Gierman LM, Kühnast S, Koudijs A, Pieterman EJ, Kloppenburg M, van Osch GJ, Stojanovic-Susulic V, Huizinga TW, Princen HM, Zuurmond AM. Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis. **Ann Rheum Dis** 2014; 73: 921-927. doi: 10.1136/annrheumdis.2013.203248.

Gierman LM, van der Ham F, Koudijs A, Wielinga PY, Kleemann R, Kooistra T, Stoop R, Kloppenburg M, van Osch GJ, Stojanovic-Susulic V, Huizinga TW, Zuurmond AM. Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice. **Arthritis Rheum** 2012; 64:1172-1181. doi: 10.1002/art.33443.

Drug and dietary intervention studies in huCRP transgenic mice

Kozijn AE, Tartjono MT, Ravipati S, van der Ham F, Barrett DA, Mastbergen SC, Korthagen NM, Lafeber FPJG, Zuurmond AM, Bobeldijk I, Weinans H, Stoop R. Human C-reactive protein aggravates osteoarthritis development in mice on a high-fat diet. **Osteoarthritis Cartilage** 2019; 27:118-128. doi: 10.1016/j.joca.2018.09.007.

Morrison MC, Yakala GK, Liang W, Wielinga PY, Salic K, van Koppen A, Tomar T, Kleemann R, Heeringa P, Kooistra T. Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21? **Sci Rep.** 2017; 6: 7: 2915. doi: 10.1038/s41598-017-02444-2.

Gierman LM, van der Ham F, Koudijs A, Wielinga PY, Kleemann R, Kooistra T, Stoop R, Kloppenburg M, van Osch GJ, Stojanovic-Susulic V, Huizinga TW, Zuurmond AM. Metabolic stress-induced inflammation plays a major role in the development of osteoarthritis in mice. **Arthritis Rheum** 2012; 64:1172-1181. doi: 10.1002/art.33443.

Rein D, Schijlen E, Kooistra T, Herbers K, Verschuren L, Hall R, Sonnewald U, Bovy A, Kleemann R. Transgenic flavonoid tomato intake reduces C-reactive protein in human C-reactive protein transgenic mice more than in wild-type tomato. **J Nutr** 2006; 136: 2331-2337. *

Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, Princen HMG, Kooistra T. Evidence for



anti-inflammatory activity of statins and PPAR α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. **Blood** **2004**; 103: 4188-4194.

Drug and dietary intervention studies in other genetically modified mouse models

Morrison MC, Egelandstal B, Harvei S, Rocha SDC, Pieterman EJ, Kleemann R, Carlsen H. Differential effects of plant and animal fats on obesity-induced dyslipidemia and atherosclerosis in Ldlr $^{-/-}$.Leiden mice. **FASEB J** **2023**; 37:e23096. doi.org/10.1096/fj.202300585R.

Seidel F, Kleemann R, van Duyvenvoorde W, van Trigt N, Keijzer N, van der Kooij S, van Kooten C, Verschuren L, Menke A, Kiliaan AJ, Winter J, Hughes TR, Morgan BP, Baas F, Fluiter K, Morrison MC. Therapeutic intervention with anti-complement component 5 antibody does not reduce NASH but does attenuate atherosclerosis and MIF concentrations in Ldlr $^{-/-}$.Leiden mice. **Int J Mol Sci.** **2022**; 23(18):10736. doi: 10.3390/ijms231810736.

Gart E, Salic K, Morrison MC, Giera M, Attema J, de Ruiter C, Caspers M, Schuren F, Bobeldijk-Pastorova I, Heer M, Qin Y, Kleemann R. The Human Milk Oligosaccharide 2'-Fucosyllactose Alleviates Liver Steatosis, ER Stress and Insulin Resistance by Reducing Hepatic Diacylglycerols and Improved Gut Permeability in Obese Ldlr $^{-/-}$.Leiden Mice. **Front Nutr** **2022**;9:904740. doi: 10.3389/fnut.2022.904740.

Gart E, van Duyvenvoorde W, Caspers MPM, van Trigt N, Snabel J, Menke A, Keijzer J, Salic K, Morrison MC, Kleemann R. Intervention with isoleucine or valine corrects hyperinsulinemia and reduces intrahepatic diacylglycerols, liver steatosis, and inflammation in Ldlr $^{-/-}$.Leiden mice with manifest obesity-associated NASH. **FASEB J** **2022**; 36(8):e22435. doi: 10.1096/fj.202200111R.

Álvarez-Amor L, Sierra AL, Cárdenas A, López-Bermudo L, López-Beas J, Andújar E, Pérez-Alegre M, Gallego-Durán R, Varela LM, Martín-Montalvo A, Berná G, Rojas A, Robles-Frías MJ, Hmadcha A, Romero-Gómez M, Kleemann R, Martín F. Extra virgin olive oil improved body weight and insulin sensitivity in high fat diet-induced obese LDLr $^{-/-}$.Leiden mice without attenuation of steatohepatitis. **Sci Rep** **2021**;11(1):8250. doi: 10.1038/s41598-021-87761-3.

Luque-Sierra A, Alvarez-Amor L, Kleemann R, Martín F, Varela LM. Extra-Virgin Olive Oil With Natural Phenolic Content Exerts an Anti-Inflammatory Effect in Adipose Tissue and Attenuates the Severity of Atherosclerotic Lesions in Ldlr $^{-/-}$.Leiden Mice. **Mol Nutr Food Res** **2018** Jul;62(13):e1800295. doi: 10.1002/mnfr.201800295

Woudstra L, Meinster E, VAN Haren L, Kay AM, Koopman M, Belien JAM, Morrison MC, VAN Rossum AC, Helder MN, Juffermans LJM, Niessen HWM, Krijnen PAJ. StemBell therapy stabilizes atherosclerotic plaques after myocardial infarction. **Cytotherapy** **2018**;20:1143-1154. doi: 10.1016/j.jcyt.2018.05.006.

Verschuren L, Wielinga PY, Kelder T, Radonjic M, Salic K, Kleemann R, van Ommen B, Kooistra T. A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone. **BMC Med Genomics** **2014**; 7:35. doi: 10.1186/1755-8794-7-35.

van Diepen JA, Vroegrijk IO, Berbée JF, Shoelson SE, Romijn JA, Havekes LM, Rensen PC, Voshol PJ. Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. **Am J Physiol Endocrinol Metab** **2011**; 301: E1099-1107.

Kitayama K, Nakai D, Kono K, Gerritsen-vanderHoop A, Kurata H, deWit EC, Cohen LH, InabaT, Kohama T. Novel non-systemic inhibitor of ileal apical Na $^{+}$ -dependent bile acid transporter reduces serum cholesterol levels in hamsters and monkeys. **Eur J Pharmacol** **2006**; 539: 89-98. *

Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, and Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. **J Biol Chem** **2004**; 279: 16154-16160.

Rezaee F, Maas A, de Maat MPM, Verheijen JH, Koopman J. Effect of genetic background and diet on plasma fibrinogen in mice. Possible relation with susceptibility to atherosclerosis. **Atherosclerosis** **2002**; 164: 37-44.

Draijer R, Volger OL, Dahlmans VEH, de Wit ECM, Havekes LM, Princen HMG. Hoe 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL-receptor, and reduces atherosclerosis in wild-type and LDL-receptor deficient mice. **Biochem Pharmacol** **2002**; 63: 1755-1761. *

Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HMG. Fibrates suppress bile acid synthesis via PPAR α -

mediated down-regulation of cholesterol 7 α -hydroxylase gene expression. **Arterioscler Thromb Vasc Biol** 2001; 21: 1840-1845.

Volger OL, van der Boom H, van Duyvenvoorde W, van Wijk K, Mathot J, Leenen R, Roodenburg AJC, Havekes LM, Princen HMG. Long term vitamin E feeding attenuates aortic atherosclerosis independent of plasma lipid levels in heterozygous LDL-receptor deficient mice. **Atherosclerosis** 2000; 151, 66 (abstract). *

Lansink M, Jong M, Bijsterbosch M, Bekkers M, Toet K, Havekes L, Emeis J, Kooistra T. Increased clearance explains lower plasma levels of tissue-type plasminogen activator by estradiol: evidence for potentially enhanced mannose receptor expression in mice. **Blood** 1999; 94: 13340-1336.

Jong MC, Dahlmans VEH, Princen HMG, Hofker MH, Havekes LM. Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice. **Atherosclerosis** 1998; 141 suppl: S77-S80.

Van Ree JH, Hofker MH, van den Broek WJAA, van Deursen JA, van der Boom, Frants RR, Wieringa B, Havekes LM. Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. **Biochem J** 1995; 305: 905-911.

Van Ree JH, van den Broek WJJ, Dahlmans VEH, Groot PHE, Vidgeon-Hart M, Frants RR, Wieringa B, Havekes LM, Hofker MH. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. **Atherosclerosis** 1994; 111: 25-37.

Other references related to transgenic mouse models

van Dijk RA, Kleemann R, Schaapherder AF, van den Bogaardt A, Hedin U, Matic L, Lindeman JHN. Validating human and mouse tissues commonly used in atherosclerosis research with coronary and aortic reference tissue: similarities but profound differences in disease initiation and plaque stability. **JVS: Vascular Sci** 2023. doi.org/10.1016/j.jvssci.2023.100118.

Mohanta SK, Peng L, Li Y, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed BR, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, Klupp BG, Megens RTA, Steffens S, Pelisek J, Eckstein HH, Kleemann R, Habenicht L, Mallat Z, Michel JB, Bernhagen J, Dichgans M, D'Agostino G, Guzik TJ, Olofsson PS, Yin C, Weber C, Lembo G, Carnevale D, Habenicht AJR. Neuroimmune cardiovascular interfaces control atherosclerosis. **Nature** 2022; 605: 152-159. doi.org/10.1038/s41586-022-04673-6.

Yakala GK, Cabrera-Fuentes HA, Crespo-Avilan GE, Rattanasopa C, Burlacu A, George BL, Anand K, Mayan DC, Corliano M, Hernández-Reséndiz S, Wu Z, Schwerk AMK, Tan ALJ, Trigueros-Motos L, Chèvre R, Chua T, Kleemann R, Liehn EA, Hausenloy DJ, Ghosh S, Singaraja RR. FURIN inhibition reduces vascular remodeling and atherosclerotic lesion progression in mice. **Arterioscler Thromb Vasc Biol** 2019; 39: 387-401. doi: 10.1161/ATVBAHA.118.311903.

Fuijschot WW, Morrison MC, van der Linden R, Krijnen PAJ, Zethof IPA, Theyse LFH, Kleemann R, Niessen HWM, Smulders YM. Orthopedic surgery increases atherosclerotic lesions and necrotic core area in ApoE^{-/-} mice. **Atherosclerosis** 2016; 255:164-170. doi: 10.1016/j.atherosclerosis.2016.07.909.

Vrins CL, Ottenhoff R, van den Oever K, de Waart DR, Kruijck JK, Zhao Y, van Berkel TJ, Havekes LM, Aerts JM, van Eck M, Rensen PC, Groen AK. Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein. **J Lipid Res** 2012;53: 2017-2023.

Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Teunisse AF, Jochemsen AG, Evers B, van de Water B, Gijbels MJ, van Vlijmen BJ, Havekes LM, de Winther MP. Macrophage p53 controls macrophage death in atherosclerotic lesions of Apolipoprotein E deficient mice. **Atherosclerosis** 2009; 207: 399-404.

DeRuiter MC, Alkemade FE, Gittenberger-de Groot AC, Poelmann RE, Havekes LM, van Dijk KW. Maternal transmission of risk for atherosclerosis. **Curr Opin Lipidol** 2008; 19: 333-337. **Review.**

Romijn JA, Corssmit EP, Havekes LM, Pijl H. Gut-brain axis. **Curr Opin Clin Nutr Metab Care** 2008; 11: 518-521. **Review.**

Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. **Cardiovasc Res** 2008; 79: 360-376. **Review.**

Eefting D, Grimbergen JM, de Vries MR, van Weel V, Kaijzel EL, Que I, Moon RT, Löwik CW, van Bockel JH, Quax PH. Prolonged *in vivo* gene silencing by electroporation-mediated plasmid delivery of small interfering RNA. **Hum Gene Ther** 2007;18:861-869.

Pires NM, Pols TW, de Vries MR, van Tiel CM, Bonta PI, Vos M, Arkenbout EK, Pannekoek H, Jukema JW, Quax PH, de Vries CJ. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. **Circulation** 2007;115:493-500.

van Weel V, Toes RE, Seghers L, Deckers MM, de Vries MR, Eilers PH, Sipkens J, Schepers A, Eefting D, van Hinsbergh VW, van Bockel JH, Quax PH. Natural killer cells and CD4⁺ T-cells modulate collateral artery development. **Arterioscler Thromb Vasc Biol** 2007 ;27:2310-2308.

Gautier T, Masson D, Jong MC, PaisdeBarros J-P, Duverneuil L, leGuern N, Deckert V, Dumont L, Bataille A, Zak Z, Jiang X-C, Havekes LM. Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice. **Biochem J** 2005; 385: 189-195.

Mulder M, Jansen PJ, Janssen BJA, vandeBerg WDJ, vanderBoom H, Havekes LM, deKloet RE, Ramaekers FCS and Blokland A. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. **Neurobiol Dis** 2004; 16: 212-219.

Bovenschen N, WillemsvanDijk K, Havekes LM, Mertens K and vanVlijmen BJM. Clearance of coagulation factor VIII in very low-density lipoprotein receptor knockout mice. **Br J Haematol** 2004; 126: 722-725.

Mensenkamp AR, vanLuyn MJA, Havinga R, Teusink B, Waterman IJ, Mann CJ, Elzinga BM, Verkade HJ, Zammit VA, Havekes LM, Shoulders CC, Kuipers F. The transport of triglycerides through the secretory pathway of hepatocytes is impaired in apolipoprotein E deficient mice. **J Hepatol** 2004; 40: 599-606.

Espirito Santo SMS, Pires NMM, Boesten LSM, Gerritsen G, Bovenschen N, WillemsvanDijk K, Jukema JW, Princen HMG, Bensadoun A, Wei-Ping Li, Herz J, Havekes LM, vanVlijmen BJM. Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol. **Blood** 2004; 103: 3777-3782.

Rezaee F, Gijbels MJ, Offerman E, Verheijen J. Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis. **Thromb Haemost** 2003; 90: 710-716.

Rezaee F, Gijbels MJ, Offerman EH, van der Linden M, de Maat MPM, Verheijen JH. Overexpression of fibrinogen in ApoE*3-Leiden transgenic mice does not influence the progression of diet-induced atherosclerosis. **Thromb Haemost** 2003; 88: 329-334.

Bovenschen N, Herz J, Grimbergen JM, Lenting PJ, Havekes LM, Mertens K, Van Vlijmen BJ. Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency. **Blood** 2003; 101: 3933-3939.

Post, SM, de Crom R, van Haperen R, van Tol A, Princen HMG. Increased fecal bile acid excretion in transgenic mice with elevated expression of human phospholipid transfer protein. **Arterioscler Thromb Vasc Biol** 2003; 23: 892-897.

Gerritsen G, Kypreos KE, Van Der Zee A, Teusink B, Zannis VI, Havekes LM, Van Dijk KW. Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain. **J Lipid Res** 2003;44: 408-414.

Vink A, Schoneveld AH, vanderMeer JJ, vanMiddelaar BJ, Sluijter JPG, Smeets MB, Quax PHA, Lim SK, Borst C, Pasterkamp G, deKleijn DPV. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. **Circulation** 2002; 106: 1985-1990.

Gautier T, Masson D, Jong MC, Duverneuil L, Le Guern N, Deckert V, Pais De Barros JP, Dumont L, Bataille A, Zak Z, Jiang XC, Tall AR, Havekes LM, Lagrost L. Apolipoprotein CI deficiency markedly augments plasma lipoprotein changes mediated by human cholesteryl ester transfer protein (CETP) in CETP transgenic/apoCI-knocked out mice. **J Biol Chem** 2002; 277: 31354-31363.

Von der Thüsen JH, van Vlijmen BJM, Hoebe RC, Kockx MM, Havekes LM, van Berkel TJC, Biessen EAL. Induction of atherosclerotic plaque rupture in apolipoprotein E^{-/-} mice after adenovirus-mediated transfer of p53. **Circulation** 2002; 105: 2064-2070.



Tacke PJ, Delsing DJ, Gijbels MJ, Quax PH, Havekes LM, Hofker MH, van Dijk KW. VLDL receptor deficiency enhances intimal thickening after vascular injury but does not affect atherosclerotic lesion area. **Atherosclerosis** 2002; 162: 103-110.

Gulledge AA, Rezaee F, Verheijen JH, Lord ST. A novel transgenic mouse model of hyperfibrinogenemia. **Thromb Haemost** 2001; 86: 511-516.

Mensenkamp AR, Havekes LM, Romijn JA, Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. **J Hepatol** 2001; 35: 816-22

Teusink B, Mensenkamp AR, van der Boom H, Kuipers F, Willems van Dijk K, Havekes LM. Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor. **J Biol Chem** 2001; 276:40693-40697.

Jong MC, Rensen PCN, Dahlmans VEH, van der Boom H, van Berkel TJC, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. **J Lipid Res** 2001; 42: 1578-1585.

Mulder M, Blokland A, van den Berg DJ, Schulten H, Bakker AHF, Terwel D, Honig W, de Kloet ER, Havekes LM, Steinbusch HWM, de Lange ECM. Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. **Lab Invest** 2001; 81: 953-960.

Kypreos KE, van Dijk KW, van Der Zee A, Havekes LM, Zannis VI. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. **J Biol Chem** 2001; 276: 19778-19786.

Tacke PJ, van der Zee A, Beumer TL, Florijn RJ, Gijbels MJJ, Havekes LM, Frants RR, Willems van Dijk K, Hofker MH. Effective generation of very low density lipoprotein receptor transgenic mice by overlapping genomic DNA fragments: high testis expression and disturbed spermatogenesis. **Transgenic Research** 2001; 10: 211-221.

Jaari S, Willems van Dijk K, Olkkonen VM, van der Zee A, Metso J, Havekes LM, Jauhainen, Ehnholm C. Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebetaHDL generation. **Comp Biochem Physiol** 2001; 128: 781-792.

Kypreos KE, Morani P, Willems van Dijk K, Havekes LM, Zannis VI. The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice. **Biochemistry** 2001; 40: 6027-6035.

Rezaee F, Maas A, Verheijen J, Koopman J. Increased hepatic fibrinogen B β -gene transcription is not enough to increase plasma fibrinogen levels. **Thromb Haemost** 2001; 85: 1025-1030.

Van Eck M, de Winther MPJ, Herijgers N, Havekes LM, Hofker MH, Groot PHE, Van Berkel TJC. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in apoE-deficient mice. **Arterioscler Thromb Vasc Biol** 2000; 20: 2600-2606.

Tacke PJ, Teusink B, Jong MC, Harats D, Havekes LM, Willems van Dijk K, Hofker MH. LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. **J Lipid Res** 2000; 41: 2055-2062

Herijgers N, de Winther MP, Van Eck M, Havekes LM, Hofker MH, Hoogerbrugge PM, Van Berkel TJC. Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. **J Lipid Res** 2000; 41:1402-1409.

Willems van Dijk K, Hofker MH, Havekes LM. Use of transgenic mice to study the role of apolipoprotein E in lipid metabolism and atherosclerosis. **Int J Tissue React** 2000; 22: 49-58

de Winther MPJ, Gijbels MJJ, Willems van Dijk K, Havekes LM, Hofker MH. Transgenic mouse models to study the role of the macrophage scavenger receptor class A in atherosclerosis. **Int J Tissue React** 2000; 22: 85-91

Jong MC, Havekes LM. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice. **Int J Tissue React** 2000; 22: 59-66.

Bronfman FC, Tesseur I, Hofker MH, Havekes LM, van Leuven F. No evidence for cholinergic problems in

apolipoprotein E knock out and apolipoprotein E4 transgenic mice. **Neuroscience** **2000**; 97: 411-418.

Van Eck M, Herijgers N, Willems van Dijk K, Havekes LM, Hofker MH, Groot PHE, van Berkel TJC. Effect of macrophage-derived mouse apoE, human ApoE3Leiden, and human ApoE2(arg158-cys) on cholesterol levels and atherosclerosis in apoE-deficient mice. **Arterioscler Thromb Vasc Biol** **2000**; 20: 119-127.

Willems van Dijk K, van Vlijmen BJM, de Winther MPJ, van 't Hof B, van der Zee A, van der Boom H, Havekes LM, Hofker MH. Hyperlipidemia of ApoE2(Arg158-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression. **Arterioscler Thromb Vasc Biol** **1999**; 19: 2945-2951.

Mensenkamp AR, Jong MC, van Goor H, van Luyn MJA, Bloks V, Havinga R, Voshol PJ, Hofker MH, Willems van Dijk K, Havekes LM, Kuipers F. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. **J Biol Chem** **1999**; 274: 35711-35718.

Van Vlijmen BJM, Rohlmann A, Page ST, Bensadoun A, Bos IS, van Berkel TJC, Havekes LM, Herz J. An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins. **J Biol Chem** **1999**; 274: 35219-35226.

De Winther MPJ, van KW, van Vlijmen BJM, Gijbels MJJ, Heus JJ, Wijers ER, van den Bos AC, Breuer M, Frants RR, Havekes LM, Hofker MH. Macrophage specific overexpression of the human macrophage scavenger receptor in transgenic mice, using a 180-kb yeast artificial chromosome, leads to enhanced foam cell formation of isolated peritoneal macrophages. **Atherosclerosis** **1999**; 147: 339-347.

Willems van Dijk K, van Vlijmen BJM, van 't Hof HB, van der Zee A, Santamarina-Fojo S, van Berkel TJC, Havekes LM, Hofker MH. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. **J Lipid Res** **1999**; 40: 336-344.

Jong MC, Willems van Dijk K, Dahlmans VEH, van der Boom H, Kobayashi K, Oka K, Siest G, Chan L, Hofker MH, Havekes LM. Reversal of hyperlipidemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low density lipoprotein receptor, but not by the very low density lipoprotein receptor. **Biochem J** **1999**; 338: 281-287.

Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism. Functional differences between ApoC1, ApoC2 and ApoC3. **Arterioscler Thromb Vasc Biol** **1999**; 19: 472-484.

Ehnholm S, Willems van Dijk K, van 't Hof B, van der Zee A, Olkkonen VM, Jauhiainen M, Hofker M, Havekes L, Ehnholm C. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. **J Lipid Res** **1998**; 39: 1248-1253.

Jong MC, Willems van Dijk K, van Vlijmen BJM, Hofker MH, Havekes LM. Overexpression of human apoC1 in transgenic mice inhibits binding of VLDL to LRP and the VLDL receptor. In: Atherosclerosis XI. Jocotot, Mathé D, and Fruchart JC, eds. **Elsevier Singapore** **1998**: 1011-1017.

Jong MC, Gijbels MJJ, Dahlmans VEH, van Gorp PJJ, Koopmans SJ, Ponc M, Hofker MH, Havekes LM. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. **J Clin Invest** **1998**; 101: 145-152.

Jong MC, Dahlmans VEH, Hofker MH, Havekes LM. Nascent very low density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. **Biochem J** **1997**; 328: 745-750.

Kuipers F, Jong MC, Lin Y, van Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, Moshage H, van Berkel TJC, Vonk RJ, Havekes LM. Impaired secretion of very low density lipoprotein-triglyceride by apolipoprotein E-deficient mouse hepatocytes. **J Clin Invest** **1997**; 100: 2915-2922.

Krugers HJ, Mulder M, Korf J, Havekes L, de Kloet ER, Joëls M. Altered synaptic plasticity in hippocampal CA1 area of apolipoprotein E deficient mice. **NeuroReport** **1997**; 8: 2505-2510.

Oitzl MS, Mulder M, Lucassen PJ, Havekes LM, Grootendorst J, de Kloet R. Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. **Brain Res.** **1997**; 752: 189-196.

Jong MC, van Ree JH, Dahlmans VEH, Frants RR, Hofker MH, Havekes LM. Reduced very low density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. **Biochem J** **1997**; 321: 445-450.

Jong M, Dahlmans V, van Gorp P, Willems van Dijk K, Breuer M, Hofker M, Havekes LM. In the absence of low density



lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor associated protein (RAP)-sensitive pathway. **J Clin Invest** **1996**; 98: 2259-2267.

Kuipers F, van Ree JM, Hofker MH, Wolters H, In 't Veld G, Havinga R, Vonk RJ, Princen HMG, Havekes LM. Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver. **Hepatology** **1996**; 24: 241-247.

Van Ree JH, van den Broek WJAA, Dahlmans VEH, Wieringa B, Frants RR, Havekes LM, Hofker MH. Variability in cholesterol content in serum and aortic tissue in apolipoprotein E-deficient mice is comparable in inbred (129/Sv) and outbred (mixed 129/Sv and C57BL/6) mice. **Atherosclerosis** **1995**; 118: 165-167.

Van Ree JH, van den Broek WJJA, van der Zee A, Dahlmans VEH, Wieringa B, Frants RR, Havekes LM, Hofker MH. Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. **Hum Molec Genet** **1995**; 4: 1403-1409.

Van Ree JH, Gijbels MJJ, van den Broek WJAA, Hofker MH, Havekes LM. Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. **Atherosclerosis** **1995**; 112: 237-243.